<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004954.pub3" GROUP_ID="STROKE" ID="138504020317554774" MERGED_FROM="" MODIFIED="2014-10-27 14:40:04 +0000" MODIFIED_BY="Hazel Fraser" REVIEW_NO="01030001" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-10-27 14:40:04 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE>Hyperbaric oxygen therapy for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2014-10-27 14:40:04 +0000" MODIFIED_BY="Hazel Fraser"><PERSON ID="4464" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Bennett</LAST_NAME><SUFFIX>FANZCA, MM(Clin Epi), MD</SUFFIX><POSITION>Director of Operating Theatres (Anaesthesia)</POSITION><EMAIL_1>m.bennett@unsw.edu.au</EMAIL_1><EMAIL_2>s9400356@unsw.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Department of Anaesthesia</DEPARTMENT><ORGANISATION>Prince of Wales Hospital</ORGANISATION><ADDRESS_1>Barker Street</ADDRESS_1><CITY>Randwick</CITY><ZIP>2031</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9382 3880</PHONE_1><PHONE_2>+61 2 9382 2222</PHONE_2><FAX_1>+61 2 9382 3882</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-10-27 14:40:04 +0000" MODIFIED_BY="Hazel Fraser"><PERSON ID="4464" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Bennett</LAST_NAME><SUFFIX>FANZCA, MM(Clin Epi), MD</SUFFIX><POSITION>Director of Operating Theatres (Anaesthesia)</POSITION><EMAIL_1>m.bennett@unsw.edu.au</EMAIL_1><EMAIL_2>s9400356@unsw.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Department of Anaesthesia</DEPARTMENT><ORGANISATION>Prince of Wales Hospital</ORGANISATION><ADDRESS_1>Barker Street</ADDRESS_1><CITY>Randwick</CITY><ZIP>2031</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9382 3880</PHONE_1><PHONE_2>+61 2 9382 2222</PHONE_2><FAX_1>+61 2 9382 3882</FAX_1></ADDRESS></PERSON><PERSON ID="z1402250836578477627303389096760" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Weibel</LAST_NAME><EMAIL_1>Weibel_S@ukw.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesia and Critical Care</DEPARTMENT><ORGANISATION>University of Würzburg</ORGANISATION><ADDRESS_1>Oberduerrbacher Str. 6</ADDRESS_1><CITY>Würzburg</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-931-201-30310</PHONE_1></ADDRESS></PERSON><PERSON ID="11165" ROLE="AUTHOR"><FIRST_NAME>Jason</FIRST_NAME><LAST_NAME>Wasiak</LAST_NAME><POSITION>Research Manager</POSITION><EMAIL_1>Jason.Wasiak@epworth.org.au</EMAIL_1><EMAIL_2>jwasiak1971@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Orthopaedic Surgery</DEPARTMENT><ORGANISATION>The Epworth Hospital</ORGANISATION><ADDRESS_1>89 Bridge Rd</ADDRESS_1><CITY>Richmond</CITY><ZIP>3121</ZIP><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 9076 3626</PHONE_1><FAX_1>+61 3 9276 6568</FAX_1></ADDRESS></PERSON><PERSON ID="B0F2D5A782E26AA20130726FEFEAE5AA" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alexander</FIRST_NAME><LAST_NAME>Schnabel</LAST_NAME><EMAIL_1>alexander_schnabel@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Anaesthesia and Critical Care</DEPARTMENT><ORGANISATION>University of Würzburg</ORGANISATION><ADDRESS_1>Oberduerrbacher Str. 6</ADDRESS_1><CITY>Würzburg</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 251 4909541</PHONE_1></ADDRESS></PERSON><PERSON ID="18576" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christopher</FIRST_NAME><LAST_NAME>French</LAST_NAME><SUFFIX>FRACP</SUFFIX><EMAIL_1>frenchc@unimelb.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine (RMH)</DEPARTMENT><ORGANISATION>University of Melbourne</ORGANISATION><ADDRESS_1>MBC Neurosciences Building</ADDRESS_1><ADDRESS_2>Parkville</ADDRESS_2><CITY>Melbourne</CITY><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="11171" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><LAST_NAME>Kranke</LAST_NAME><SUFFIX>MD, PhD, MBA</SUFFIX><POSITION>Professor of Anaesthesia</POSITION><EMAIL_1>peter.kranke@t-online.de</EMAIL_1><URL>http://anaesthesie.uk-wuerzburg.de/klinische-studien.html</URL><MOBILE_PHONE>+49 160 90 55 11 74</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Anaesthesia and Critical Care</DEPARTMENT><ORGANISATION>University of Würzburg</ORGANISATION><ADDRESS_1>Oberdürrbacher Str. 6</ADDRESS_1><CITY>Würzburg</CITY><ZIP>97080</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 931 201 30050</PHONE_1><PHONE_2>+49 931 201 30021 (secretary)</PHONE_2><FAX_1>+49 931 201 30053</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-07-09 08:26:59 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="9" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="4" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-10-10 11:34:59 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-10 11:34:52 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Conclusions have not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-10 11:34:59 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>We have included in the qualitative review one trial that was previously excluded and two new citations, all of which are randomised controlled trials (RCTs) but do not report any outcomes of interest. The review now includes 11 RCTs involving 705 participants. One new citation was added to the quantitative synthesis, but conclusions have not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="31" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>This review has been updated to 31 December 2008. We have included three new studies, but no substantial changes have been made to the conclusions. Six further studies previously awaiting classification have now been excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="20" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>This review has been converted to the new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-05-27 14:49:39 +0100" MODIFIED_BY="Hazel Fraser">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-10-10 12:10:31 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2014-10-10 11:38:25 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2014-10-10 11:37:29 +0100" MODIFIED_BY="Hazel Fraser">Hyperbaric oxygen therapy for treating people with acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2014-10-10 11:38:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>
<B>Question</B>
</P>
<P>We wanted to compare the safety and effectiveness of hyperbaric oxygen therapy (HBOT) versus no HBOT (either no treatment or an ineffective intervention designed to mimic the true treatment) for treating people who had suffered an acute ischaemic stroke.</P>
<P>
<B>Background</B>
</P>
<P>Hyperbaric oxygen therapy (HBOT) is a treatment designed to increase the supply of oxygen to the part of the brain affected by stroke and to reduce the extent of irreversible damage. HBOT involves people breathing pure oxygen in a specially designed chamber (such as those used for deep sea divers with the bends) for a period of about an hour and a half each day for 10 to 20 days.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We identified 11 studies, involving 705 participants, up to April 2014. All studies included adult participants (41% female) who had suffered an acute stroke within the past two weeks, although most studies enrolled participants within three days of the stroke. All trials evaluated the addition of HBOT to standard practice for study participants. Most trials reported the number of deaths and some measure of functional ability, although the actual measures used varied considerably, making comparisons between trials difficult. Follow-up periods varied from 90 days to one year.</P>
<P>
<B>Key results</B>
</P>
<P>Too few patients have been studied to say whether HBOT decreases the chance of dying, and only three trials have suggested improvement in the ability to do everyday tasks. Overall, little evidence is currently available to support the use of HBOT for people with stroke.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>In general, the quality of the evidence was moderate, given the small numbers of participants and the many different instruments used to estimate the quality of life and the functional ability of participants. The methodology used in many of these trials was poorly described, making a good estimate of the reliability of the evidence difficult. We could pool data only for the chance of dying after the stroke, and although no evidence suggested that HBOT reduced the chance of death following a stroke, the confidence we have in this result is relatively low. We have not excluded the possibility that HBOT may be harmful or beneficial.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-10-10 11:37:17 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2014-10-10 11:35:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Most cases of stroke are caused by impairment of blood flow to the brain (ischaemia), which results in a reduction in available oxygen and subsequent cell death. It has been postulated that hyperbaric oxygen therapy (HBOT) may reduce the volume of brain that will die by greatly increasing available oxygen, and it may further improve outcomes by reducing brain swelling. Some centres are using HBOT routinely to treat people with stroke. This is an update of a Cochrane Review first published in 2005.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-10-10 11:35:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effectiveness and safety of adjunctive HBOT in the treatment of people with acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-10-10 11:36:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched April 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (April 2014), MEDLINE (1966 to April 2014), EMBASE (1980 to April 2014), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to April 2014), the Database of Randomised Controlled Trials in Hyperbaric Medicine (DORCTIHM) (searched April 2014) and the reference lists of articles. We handsearched relevant publications and contacted researchers to identify additional published and unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-10-10 11:36:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised controlled trials (RCTs) that compared the effects of adjunctive HBOT versus those of no HBOT (no treatment or sham).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-10-10 11:36:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>Three review authors independently extracted data, assessed each trial for internal validity and resolved differences by discussion.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-10-10 11:37:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>We included 11 RCTs involving 705 participants. The methodological quality of the trials varied. We could pool data only for case fatalities. No significant differences were noted in the case fatality rate at six months in those receiving HBOT compared with the control group (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.34 to 2.75, P value 0.96). Four of 14 scale measures of disability and functional performance indicated improvement following HBOT, for example, the mean Trouillas Disability Scale score was lower with HBOT (mean difference (MD) 2.2 point reduction with HBOT, 95% CI 0.15 to 4.3, P value 0.04), and the mean Orgogozo Scale score was higher (MD 27.9 points, 95% CI 4.0 to 51.8, P value 0.02).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-10-10 11:37:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>We found no good evidence to show that HBOT improves clinical outcomes when applied during acute presentation of ischaemic stroke. Although evidence from the 11 RCTs is insufficient to provide clear guidelines for practice, the possibility of clinical benefit has not been excluded. Further research is required to better define the role of HBOT in this condition.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-10-10 12:10:31 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<CONDITION MODIFIED="2014-10-10 11:39:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>Stroke may be defined as a sudden neurological deficit of presumed vascular origin (<LINK REF="REF-Bath-2000" TYPE="REFERENCE">Bath 2000</LINK>). It is both a leading cause of mortality worldwide, accounting for an estimated 4.4 million deaths in 1990 (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>), and a leading cause of disability. About one-third of survivors require significant assistance in daily life at one year after the event (<LINK REF="REF-Bamford-1991" TYPE="REFERENCE">Bamford 1991</LINK>; <LINK REF="REF-Bath-2000" TYPE="REFERENCE">Bath 2000</LINK>).</P>
<P>Stroke is divided into two broad subgroups: ischaemic (impairment of blood flow) and haemorrhagic (bleeding within the brain), with the former accounting for 73% to 86% of all cases (<LINK REF="REF-Sudlow-1997" TYPE="REFERENCE">Sudlow 1997</LINK>). On average, ischaemic stroke has a lower case fatality rate than haemorrhagic stroke (23% versus 62% at one year), and treatment differs for the two subgroups (<LINK REF="REF-Bamford-1991" TYPE="REFERENCE">Bamford 1991</LINK>; <LINK REF="REF-Bath-2000" TYPE="REFERENCE">Bath 2000</LINK>). Therefore, early and accurate diagnosis is desirable. Because clinical assessment is unreliable in determining stroke type, neuroimaging (preferably using computerised tomography (CT) scan) is required for optimal management (<LINK REF="REF-Wardlaw-2004" TYPE="REFERENCE">Wardlaw 2004</LINK>).</P>
<P>During a cerebral ischaemic event, neurological tissue suffers hypoxia. When hypoxia is prolonged, neurons lose their ability to maintain ionic homeostasis. Free oxygen radicals accumulate and degrade the cell membranes (<LINK REF="REF-Ikeda-1990" TYPE="REFERENCE">Ikeda 1990</LINK>; <LINK REF="REF-Siesjo-1989" TYPE="REFERENCE">Siesjo 1989</LINK>); irreversible changes result in unavoidable cell death. These changes may occur rapidly and before therapy can be instituted, but in some people the symptoms worsen gradually or in a step-wise fashion over a matter of hours or days (<LINK REF="REF-Robertson-1989" TYPE="REFERENCE">Robertson 1989</LINK>). This latter observation suggests that close management of haemodynamic, respiratory and metabolic factors designed to maintain oxygenation might be beneficial. Indeed, intensive stroke management protocols and antiplatelet therapy have been shown to positively influence the outcome (<LINK REF="REF-CASTCG-1997" TYPE="REFERENCE">CASTCG 1997</LINK>; <LINK REF="REF-ISTCG-1997" TYPE="REFERENCE">ISTCG 1997</LINK>; <LINK REF="REF-SUTC-2004" TYPE="REFERENCE">SUTC 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-10-10 11:39:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>Hyperbaric oxygen therapy (HBOT) is an adjunctive therapy that has been proposed for the treatment of people with ischaemic stroke (<LINK REF="REF-Hart-1971" TYPE="REFERENCE">Hart 1971</LINK>; <LINK REF="REF-Ingvar-1965" TYPE="REFERENCE">Ingvar 1965</LINK>). HBOT is the therapeutic administration of 100% oxygen at environmental pressures greater than 1.0 atmosphere absolute (ATA). Administration involves placing the patient in an airtight vessel, increasing pressure within that vessel and administering 100% oxygen for respiration. In this way, it is possible to deliver greatly increased partial pressure of oxygen to the tissues. Typically, treatments involve pressurisation to between 1.5 and 3.0 ATA for periods between 60 and 120 minutes, once or twice daily.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-10-10 11:40:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>Potential benefits of HBOT include reversal of hypoxia through increased oxygen delivery and reduction of cerebral oedema (<LINK REF="REF-Hills-1999" TYPE="REFERENCE">Hills 1999</LINK>; <LINK REF="REF-Sukoff-1982" TYPE="REFERENCE">Sukoff 1982</LINK>), as well as several specific effects of hyperoxia, which include decreased lipid peroxidation, inhibition of leucocyte activation and restoration of the functional blood-brain barrier (<LINK REF="REF-Mink-1995a" TYPE="REFERENCE">Mink 1995a</LINK>; <LINK REF="REF-Mink-1995b" TYPE="REFERENCE">Mink 1995b</LINK>; <LINK REF="REF-Thom-1993" TYPE="REFERENCE">Thom 1993</LINK>). It has been proposed that HBOT protects marginally viable brain (often termed 'the ischaemic penumbra') from further damage on reperfusion through these mechanisms, which act to regulate abnormal cellular metabolites (<LINK REF="REF-Badr-2001" TYPE="REFERENCE">Badr 2001</LINK>; <LINK REF="REF-Selman-2004" TYPE="REFERENCE">Selman 2004</LINK>). Conversely, oxygen in high doses may increase oxidative stress through the production of oxygen free-radical species and is potentially toxic (<LINK REF="REF-Yusa-1987" TYPE="REFERENCE">Yusa 1987</LINK>). Indeed, the brain is particularly at risk (<LINK REF="REF-Clark-1982" TYPE="REFERENCE">Clark 1982</LINK>). For this reason, it is appropriate to postulate that in some people with stroke, HBOT may do more harm than good.</P>
<P>Therefore, HBOT is associated with some risk of adverse effects, including damage to the ears, sinuses and lungs from the effects of pressure, temporary worsening of shortsightedness, claustrophobia and oxygen poisoning. Although serious adverse events are rare, HBOT cannot be regarded as an entirely benign intervention.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>Despite 40 years of interest in the delivery of HBOT for people with stroke, little comparative evidence of effectiveness can be found. Most reports have described single or multiple cases, and the largest study includes a series of 122 cases reported in 1980 (<LINK REF="REF-Neubauer-1980" TYPE="REFERENCE">Neubauer 1980</LINK>). A review of these studies revealed that more than half of cases improved clinically or electrophysiologically with HBOT and concluded that a case could be made for setting up controlled studies (<LINK REF="REF-Nighoghossian-1997" TYPE="REFERENCE">Nighoghossian 1997</LINK>).</P>
<P>This is an update of a Cochrane review first published in 2005.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-10-10 11:40:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effectiveness and safety of adjunctive HBOT in the treatment of people with acute ischaemic stroke.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-10-10 11:44:28 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2014-10-10 11:41:34 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES MODIFIED="2014-10-10 11:40:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>We included all randomised controlled trials (RCTs) that compared the effects of adjunctive HBOT versus those of no HBOT (no treatment or sham).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-10-10 11:40:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>We focused on participants of any age or sex with acute ischaemic stroke. Acute ischaemic stroke was defined as a sudden neurological deficit of presumed vascular origin for which haemorrhage had been excluded by CT or magnetic resonance imaging (MRI) within 14 days of enrolment in the trial.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-10-10 11:41:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>Trials comparing standard treatment regimens designed to promote recovery after acute ischaemic stroke, including intensive combined therapies, with and without HBOT.</P>
<P>Studies were eligible for inclusion if HBOT was administered in a compression chamber at pressures between 1.5 ATA and 3.0 ATA for treatment times between 30 minutes and 120 minutes, at least once daily.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-10-10 11:41:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>Studies were eligible for inclusion in the meta-analysis if they reported any of the following outcome measures. Because of variations in clinical practice, we divided timing and recording of outcomes into three stages for analysis: early (immediately after the treatment course), medium term (four to eight weeks after treatment) and longer term (at the end of scheduled follow-up). Several assessment scales were used to quantify trial outcomes. We have taken information concerning these scales from the Internet Stroke Centre Stroke Trials Directory at <A HREF="http://www.strokecenter.org/trials/scales/index.htm">http://www.strokecenter.org/trials/scales/index.htm</A>.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-10-10 11:41:20 +0100" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>Case fatality rate.</LI>
<LI>Severe functional disability rate (or death), defined as 'drowsy/stuporous/unconscious or unable to feed/dress independently.' Care was taken to ensure that death was included as a bad outcome when data were extracted.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-10-10 11:41:34 +0100" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>Functional status scale scores (e.g. National Institutes of Health Stroke Scale (NIHSS), Rankin Score, Glasgow Outcome Scale).</LI>
<LI>Deemed to have a good functional outcome assessed as a binary outcome using any of the above scales.</LI>
<LI>Activities of daily living (ADLs) (e.g. the Barthel Index).</LI>
<LI>CT or MRI estimate of infarct size or volume.</LI>
<LI>Adverse events following HBOT, such as proportion of participants with visual disturbance (short and long term), barotrauma (aural, sinus, pulmonary short and long term) and oxygen toxicity (short term); other recorded adverse effects were reported and discussed.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-10-10 11:42:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>See the 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module.</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-10-10 11:42:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Managing Editor on 3 April 2014. In addition, we searched MEDLINE (1966 to April 2014; <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE (1980 to April 2014; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to April 2014; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), as well as the Cochrane Central Register of Controlled Trials (CENTRAL) (8 April 2014; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We adapted the MEDLINE search strategy for the other databases. We applied no language restrictions. We also searched the Database of Randomised Controlled Trials in Hyperbaric Medicine (DORCTIHM) (from inception to April 2014) (<LINK REF="REF-Bennett-2004" TYPE="REFERENCE">Bennett 2004</LINK>). The DORCTIHM database was compiled through an unfocused search of PubMed using 'hyperbaric oxygenation' as a medical subject heading (MeSH) term, handsearching of primarily hyperbaric journals (see below) since first publication and checking of references in identified RCTs. This site is now interactive and receives citations for formal review from healthcare professionals in the field.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-10-10 11:42:40 +0100" MODIFIED_BY="Hazel Fraser">
<OL>
<LI>We searched the reference lists of articles and contacted researchers in an effort to identify additional published and unpublished studies.</LI>
<LI>We handsearched the following relevant publications.</LI>
<OL>
<LI>Hyperbaric textbooks (<LINK REF="REF-Jain-1999" TYPE="REFERENCE">Jain 1999</LINK>; <LINK REF="REF-Jain-2009" TYPE="REFERENCE">Jain 2009</LINK>; <LINK REF="REF-Kindwall-1999" TYPE="REFERENCE">Kindwall 1999</LINK>; <LINK REF="REF-Mathieu-2006" TYPE="REFERENCE">Mathieu 2006</LINK>; <LINK REF="REF-Oriani-1996" TYPE="REFERENCE">Oriani 1996</LINK>).</LI>
<LI>Journals (<I>Undersea and Hyperbaric Medicine </I>1992 to 2014, <I>Hyperbaric Medicine Review</I> 1986 to 1992, <I>South Pacific Underwater Medicine Society (SPUMS) Journal</I> 1973 to 2007, <I>European Journal of Hyperbaric Medicine</I> 1998 to 2007, <I>Diving and Hyperbaric Medicine</I> 2007 to 2014 and <I>Aviation, Space and Environmental Medicine Journal</I> 1980 to 2014).</LI>
<LI>Conference proceedings (Undersea and Hyperbaric Medical Society, SPUMS, European Undersea and Baromedical Society, International Congress of Hyperbaric Medicine) published from 1980 to 2014.</LI>
</OL>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-10-10 11:44:28 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Trial identification</HEADING>
<P>Three review authors (MB, JW and PK) scanned records identified through the electronic searches and excluded obviously irrelevant studies. Two review authors (MB and AS) assessed the remaining records and retrieved the full-text articles of all potentially relevant studies. From these, three review authors (MB, AS and PK) selected studies for inclusion based on the criteria described previously. In all instances, review authors resolved differences of opinion by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Three review authors (MB, AS and CF) independently extracted data from the studies using standardised forms developed for this review. We contacted the authors of primary studies to request further information when data were missing or incomplete. Review authors resolved all differences by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>We assessed study quality using the 'Risk of bias' tables for each individual study, as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>); the results are presented both descriptively and graphically.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analyses</HEADING>
<P>We used a fixed-effect model when no evidence of significant heterogeneity between studies was found and planned to use a random-effects model when such heterogeneity was likely (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). We considered the appropriateness of meta-analysis in the presence of significant clinical or statistical heterogeneity. We assessed statistical heterogeneity using the I<SUP>2</SUP> statistic. We planned to explore heterogeneity and to perform subgroup analyses if appropriate.</P>
<P>For proportions (dichotomous outcomes), we used risk ratio (RR). We converted continuous data to mean differences (MDs) using the inverse variance method and calculated an overall MD. We planned to test publication bias using funnel plots; however, this was not appropriate given the small number of studies found.</P>
<P>We planned to perform subgroup analysis by calculating the RR or MD in each subgroup and examining 95% confidence intervals (CIs). Non-overlap in intervals would have been taken to indicate a statistically significant difference between subgroups; however, subgroup analysis was not appropriate given the available data.</P>
<P>All analyses were performed on an intention-to-treat basis, if possible, and if not possible, this was clearly stated.</P>
<P>We intended to perform sensitivity analyses for missing data and study quality, if appropriate.</P>
<SUBSECTION>
<HEADING LEVEL="4">Missing data</HEADING>
<P>We had planned to employ sensitivity analyses by using different approaches to imputing missing data. However, no binary outcomes involved incomplete data, and this analysis was not required.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study quality</HEADING>
<P>If appropriate, we had planned to conduct a sensitivity analysis by study quality based on the presence or absence of a reliable random allocation method, concealment of allocation and blinding of participants or outcome assessors.</P>
<P>If appropriate data were found, we planned to consider subgroup analysis based on the following.<BR/>
</P>
<OL>
<LI>Time elapsed between stroke and institution of HBOT.</LI>
<LI>Dose of oxygen received (pressure less than 2.0 ATA versus greater than or equal to 2.0 ATA), time of treatment (less than 60 minutes versus 60 minutes or longer) and length of treatment course (fewer than five sessions versus five or more sessions).</LI>
<LI>Nature of comparative treatment modalities.</LI>
<LI>Volume of cerebral infarction as measured by baseline presentation of CT imaging.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-10-10 12:10:20 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2014-10-10 12:10:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>We identified a total of 962 references in 2004, a further 104 by September 2008 and a further 396 by April 2014, yielding a total of 1462 citations. Following elimination of duplicates, independent scrutiny of the titles and abstracts revealed 40 potentially relevant articles. One was an ongoing trial first announced in 2008 (<LINK REF="STD-Michalski-2008" TYPE="STUDY">Michalski 2008</LINK>), but our attempts to contact the study authors were unsuccessful, and this trial may have been abandoned. Following review of the full text of the remaining 39 articles, we excluded 18 further trials because they were not RCTs, five because they gave inappropriate treatment, four because they included inappropriate participants (with long-standing or haemorrhagic stroke) and one review article (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The remaining 11 randomised trials formed the basis of this review and are described below. Seven trials are now included in the quantitative review.</P>
<P>Between the previous search in September 2008 and the most recent search in April 2014, we found 396 new citations, of which only one was a new trial, which contributed 38 further participants to the quantitative analysis (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>). In this review, we also included four relevant trials that did not report on our outcomes of interest and so did not contribute to the quantitative review. Together these trials enrolled a total of 334 participants.</P>
<P>In total, the 11 included trials enrolled 705 participants (361 into trials contributing to the quantitative review and 344 into trials contributing to the qualitative review only).</P>
<P>
<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> enrolled 39 non-pregnant participants (sex distribution was not given) between 20 and 90 years of age, presenting with a neurological deficit and score greater than 20 on a scale devised for this trial (0 = no deficit, 100 = completely unresponsive). The deficit was presumed to be due to ischaemic cerebral infarction in the brain region perfused by one carotid artery and to have occurred during the preceding two weeks. Once enrolled, all participants received standard care in a neurological intensive care unit and 400 mg of vitamin A daily. Those randomly assigned to the HBOT arm received 100% oxygen (for 60 minutes at 1.5 ATA) every eight hours to a total of 15 sessions, and those in the control arm received a sham treatment of breathing air (at 1.5 ATA) on the same schedule. Changes in the graded neurological examination performed on admission were used to assess neurological outcomes at day five, week six and year one. Infarct volume was estimated by CT at four months, and deaths were recorded.</P>
<P>
<LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> enrolled 34 participants (21 men), between 20 and 75 years of age, presenting with a neurological deficit highly suggestive of middle cerebral artery (MCA) occlusion. All participants presented within 24 hours of the cerebral event and with a score less than 80 on the Orgogozo Functional Scale (0 = completely unresponsive, 100 = no deficit). Once enrolled, all participants received supportive care including low-dose heparin (10,000 units divided into two doses daily), nursing care, rehabilitation, speech therapy and occupational therapy. Those allocated to HBOT received 100% oxygen (in a monoplace chamber at 1.5 ATA daily for 40 minutes for 10 days), while controls received sham therapy (at 1.2 ATA) of breathing air on the same schedule. Outcomes included case fatality rate and changes on three healthcare scales (acute assessment scale: Orgogozo (100 to 0), Trouillas (0 to 10) and functional assessment scale (Rankin Scale)) that were used to assess neurological outcomes at six months and at one year.</P>
<P>
<LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK> has been presented only in abstract format. This trial enrolled 17 participants with an average age of 62 years who had presented for therapy within 24 hours of CT scanning, showing a cerebral ischaemic event in the middle or anterior cerebral arterial territory. Study participants included 11 males. The degree of neurological deficit was not clear, although scores were provided in a table. Once enrolled, participants were randomly assigned by a method not stated to receive HBOT (1.5 to 1.8 ATA for 60 minutes daily for 8 to 10 days) or sham treatment of breathing air. A neurological recovery score (0 to 10) was used to assess outcomes at six and 12 months.</P>
<P>
<LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> enrolled 33 participants (including 22 men) presenting to the emergency department within 24 hours of stroke onset with a deficit on an acute impairment scale&#8212;the National Institutes of Health Stroke Scale (NIHSS)&#8212;of less than 23 (30 is maximum disability) and without evidence of haemorrhage on CT. Those randomly assigned to the HBOT arm received a single session (breathing 100% oxygen for 60 minutes in a monoplace chamber at 2.5 ATA), while those in the control arm received sham treatment (breathing oxygen at 1.14 ATA). Primary outcome measures included percentages of participants with improvement at 24 hours and at 90 days. Secondary measurements included complications of treatment and mortality at 90 days. Outcomes included case fatality rate; adverse effects of treatment and changes in the following: NIHSS score (at 24 hours and at 90 days); a functional assessment scale&#8212;the modified Rankin Scale (90 days); and two outcome scales&#8212;the Barthel Index of ADL (90 days) and the Glasgow Outcome Scale (90 days).</P>
<P>
<LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK> enrolled 80 participants (43 men) with radiological or MRI evidence of ischaemic stroke within 72 hours of the event. These strokes occurred in a range of vascular territories. Participants were randomly assigned to receive HBOT at 2.0 ATA for 80 minutes daily, probably for 20 days, or a standard therapy that may have included a vasodilator, an anticoagulant or a 'nerve cell protectant.' The only outcome measure was a four-point scale from 'cure' to 'no effect' that was measured at 21 days.</P>
<P>
<LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK> enrolled 120 participants with radiological or MRI evidence of ischaemic stroke within 72 hours of the event; however 40 of these were randomly assigned to an arm that was not relevant to this review. The strokes were all 'first events,' associated with neurological deficits and during which the patient was conscious and co-operative. Eighty participants were randomly assigned to HBOT at 2.0 ATA for 60 minutes daily for 20 days or to a standard treatment regimen that was not described in detail. Outcomes measured include degree of neurological dysfunction (scale not described), Fugl-Meyer motor assessment score and Barthel Index of activities of daily living. The timing of these assessments was not stated.</P>
<P>
<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK> enrolled 38 adult participants with acute embolic stroke in the MCA territory within 48 hours of the event. Initial diagnosis was determined by neurological signs and was confirmed by MRI. Patients were excluded if they had received fibrinolytic therapy. All participants received standard care plus a free-radical scavenger&#8212;edaravone 30 mg intravenously twice daily. In addition, the 19 participants in the HBOT group received 100% oxygen at 2.0 ATA for 60 minutes daily for 10 days. Reported outcomes included death, unfavourable outcomes by the Modified Rankin Scale (mRS), adverse events and median NIHSS scores&#8212;all at 90 days.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trials included but not contributing to the quantitative review</HEADING>
<P>
<LINK REF="STD-Li-1998" TYPE="STUDY">Li 1998</LINK> enrolled 86 participants with cerebral infarction (time not stated but described as 'acute') and provided 'routine' therapy with 'Salvia Milirrhiza Co.' to both groups. The 43 participants assigned to the HBOT group received 10 daily treatments at 2 ATA breathing 100% oxygen for 120 minutes. The study authors reported cerebral blood flow, electroencephalography (EEG), haemorrheology and serum superoxide dismutase (SOD) before and after the intervention period but included no outcomes of interest for this review. EEG, cerebral blood flow and serum SOD were reported as improved in the HBOT group versus the control group (P value &lt; 0.01). Haemorrheology was not significantly different.</P>
<P>
<LINK REF="STD-Peng-2003" TYPE="STUDY">Peng 2003</LINK> enrolled 60 participants with cerebral infarction within the previous seven days, and 30 were allocated to each arm of the study. All participants received 'standard pharmacological care,' while the HBOT group received 10 daily treatments at 2.3 ATA breathing 100% oxygen for 80 minutes. The study authors reported within-group differences for several markers of free-radical activity, including serum nitric oxide (NO), SOD and monoaldehyde (MDA) but did not directly compare groups. Levels of NO and SOD were significantly increased following HBOT, but not in the control group. Participants in the HBOT group had significantly improved scores on an undefined neurological deficit scale (HBOT 9 ± 8 versus 15 ± 9, t = -2.176, P value &lt; 0.05). Researchers also reported improved 'clinical efficacy' in the HBOT group (HBOT 87% versus control 63%, x<SUP>2 </SUP>= 4.356, P value &lt; 0.05).</P>
<P>
<LINK REF="STD-Hong-2008" TYPE="STUDY">Hong 2008</LINK> is an abstract only and has not been published in full. This trial enrolled 86 young inpatients with ischaemic stroke, but there are no further details. The cohort was randomised into two groups (method unknown), but the number of participants in each group is not given. One group received 'routine therapy' while the other received 'routine therapy and hyperbaric therapy'. Neither treatment arm was described. The authors reported the 'Nerve Function Deficit Score' (undefined) was improved in 70% in the HBOT group and 42.6% in the control group, that the effectiveness of treatment in the HBOT group was 81.4% compared with 35.9% in the control group, and that the total progress rate was 93% versus 60.5% in favour of the HBOT group. None of these outcomes were defined.</P>
<P>
<LINK REF="STD-Zhao-2008" TYPE="STUDY">Zhao 2008</LINK> enrolled 112 adults admitted with an acute stroke involving the internal carotid artery territory and confirmed with CT or MRI within 24 hours. They were randomised by a method not described. Sixty-two participants received routine therapy including anticoagulation, antiplatelet aggregation agents, cerebral vasodilators, reduction of intracranial pressure by dehydration, as well as supplementary rehabilitation exercise. Fifty participants received the same routine treatment plus HBOT for 60 minutes daily for 10 days at 2.0 ATA (plus a 30-minute decompression). Serum levels of soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, soluble E-selectin, and matrix metalloproteinase-9 were significantly increased on admission and decreased over the study period in both groups. The decrease was significantly greater in the HBO group, compared with the routine treatment group (P value &lt; 0.05 or P value &lt; 0.01).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-10-10 11:53:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for further details. These trials varied in methodological quality, and only six provided full reports of completed trials in a peer-reviewed publication. Risk of bias dimensions are presented for each included study in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomisation</HEADING>
<P>Randomisation procedures were described in two trials - <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> (sealed envelopes) and <LINK REF="STD-Peng-2003" TYPE="STUDY">Peng 2003</LINK> (coin toss) - but not in the other nine trials. Allocation concealment was adequately described in <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>, but in the other 10 reports, it was not clear whether investigators were unable to predict the prospective group to which a participant would be allocated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participant baseline characteristics</HEADING>
<P>All trials enrolled participants with clinical evidence of neurological deficit attributable to ischaemic stroke and lasting longer than 24 hours. Five trials specifically excluded haemorrhagic stroke with CT or MRI evidence before the time of enrolment (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>; <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>; <LINK REF="STD-Zhao-2008" TYPE="STUDY">Zhao 2008</LINK>). Three trials enrolled participants within 24 hours of the cerebral event (<LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>; <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK>), one trial within 48 hours (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>), two trials within 72 hours (<LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>) and one trial within seven days (<LINK REF="STD-Peng-2003" TYPE="STUDY">Peng 2003</LINK>), and one trial accepted participants up to two weeks following the event (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>). The extent and severity of deficit on enrolment were poorly described and difficult to compare across trials, given the different neurological and health status scales used to establish baseline status. Three trials specified the clinical appearance of deficits in an area supplied by one internal carotid artery (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK>): Two trials specified the anterior cerebral artery territory (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>) and two the anterior or middle cerebral territory (<LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK>); three studies did not specify the area (<LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>; <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>). All trials enrolled both male and female adults. In total, 118 participants (41%) were female.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Four trials utilised sham therapy to mask participants to HBOT (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>, <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK>). Two trials blinded the investigators (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>); one trial also specified outcome assessor blinding (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>). No study author formally tested the success of the blinding strategy applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants lost to follow-up</HEADING>
<P>
<LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported a total of seven participants who were withdrawn from therapy (control group: four - all because of worsening neurological status, with one dead at six-month follow-up; HBOT group: three - one with worsening of neurological state, one with myocardial infarction and one with claustrophobia). <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> lost a total of 12 participants to follow-up at six months (control group: five - two deaths, two unavailable and one refusal; HBOT group: seven - two deaths, one unavailable, three refusals and one following a second stroke); <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> lost seven participants to final follow-up (control group: six - two dead, four not explained; HBOT group: one dead). <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK> reported a participant group of 80 but reported demographic and outcome data for only 70 participants&#8212;it is not clear whether this was an error or if 10 participants were lost to follow-up. No comparisons of baseline characteristics were made between those lost to follow-up and those remaining in the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat analysis</HEADING>
<P>Two trials performed intention-to-treat analyses as they reported inclusion of those lost to follow-up or not completing the allocated therapy (<LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>). For mortality, one trial also used intention-to-treat; however, it is not clear if this approach was used for other outcomes (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-10-10 11:55:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>We could pool data from only seven studies enrolling a total of 361 participants and for a limited number of clinically important outcomes. For most outcomes, we have been limited to a description of outcomes reported individually for each study.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 1. Death at three to six months</HEADING>
<P>Data were available for four trials involving 144 participants (45% of the total participants in this review) (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>; <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>; ). No significant differences in case fatality rates were noted (six deaths (8%) in those receiving HBOT versus six (8.5%) among those given sham therapy). The risk ratio (RR) of dying after receiving HBOT was 0.97 (95% CI 0.34 to 2.75, P value 0.96). Moderate heterogeneity between trials was indicated (I<SUP>2</SUP> = 34.7%), which was explained by removal of the single trial testing the combination of HBOT and a free-radical scavenger (edaravone) versus edaravone only. No participants were lost to follow-up for this outcome (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 2. No effect of therapy</HEADING>
<P>Only <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK> presented data on this outcome, involving 70 participants (25% of the total). In the HBOT group, three of 38 participants (8%) were judged to have received 'no effect' from therapy and were unable to care for themselves, compared with seven of 32 cases (22%) in the control group. The risk ratio for a poor outcome with HBOT was 0.36 but was not statistically significant (95% CI 0.1 to 1.28, P value = 0.12) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 3. Functional scales</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mean neurological assessment score at day five</HEADING>
<P>Only <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> reported this outcome. The mean score was lower (better outcome) in the control group (38.5 versus 43.8: MD 5.3 points, 95% CI -7.5 to 18.1, P value 0.42) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean neurological assessment score at week six</HEADING>
<P>Only <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> reported this outcome. The mean score was lower (better outcome) in the control group (28.3 versus 38.5: MD 10.2 points, 95% CI -8.5 to 28.9, P value 0.28) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean neurological assessment score at one year</HEADING>
<P>Only <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> reported this outcome. The mean score was lower (better outcome) in the control group (25.8 versus 31.4: MD 5.6 points, 95% CI -15.0 to 26.2, P value 0.59) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Orgogozo Scale score at six months</HEADING>
<P>Only <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported this outcome. The mean score was higher (better outcome) in the HBOT group (72.9 versus 54.7: MD 18.2 points, 95% CI -5.2 to 41.6, P value 0.13) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Orgogozo Scale score at one year</HEADING>
<P>Only <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported this outcome. The mean score was higher (better outcome) in the HBOT group (78.2 versus 50.3: MD 27.9 points, 95% CI 4.0 to 51.8, P value 0.02) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Trouillas Disability Scale score at six months</HEADING>
<P>Only <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported this outcome. The mean score was lower (better outcome) in the HBOT group (4.6 versus 6.1: MD 1.5 points, 95% CI -1.2 to 4.2, P value 0.27) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Trouillas Disability Scale score at one year</HEADING>
<P>Only <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported this outcome. The mean score was lower (better outcome) in the HBOT group (4.1 versus 6.3: MD 2.2 points, 95% CI 0.15 to 4.3, P value 0.04) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Modified Rankin Functional Assessment Scale score at six months</HEADING>
<P>Only <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported this outcome. The mean score was lower (better outcome) in the HBOT group (2.6 versus 3.2: MD 0.6 points, 95% CI -0.18 to 1.4, P value 0.13) (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Modified Rankin Functional Assessment Scale score at one year</HEADING>
<P>Only <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> reported this outcome. The mean score was lower (better outcome) in the HBOT group (2.4 versus 3.0: MD 0.6 points, 95% CI -0.18 to 1.4, P value 0.13) (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Neurological Recovery Score at 12 months</HEADING>
<P>Only <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK> reported this outcome. The mean score was better in the HBOT group (HBOT score 4.2 versus control 6.4, MD 2.2 points better with HBOT, 95% CI 1.6 to 2.8, P value &lt; 0.0001) (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Neurological Functional Deficit Score at three weeks</HEADING>
<P>Only <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK> reported this outcome and did not define this scale. The mean score after therapy was better with HBOT than with sham (HBOT 17 versus control 20, MD 3 points better with HBOT, 95% CI 0.4 to 5.6, P value 0.03) (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 4. Deemed to have a good outcome</HEADING>
<P>Two trials reported the numbers of participants achieving a predefined 'good outcome' (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>). <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> used four different outcome scales, and <LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK> used the Modified Rankin Scale. Differences are reported below.</P>
<SUBSECTION>
<HEADING LEVEL="5">NIHSS zero or improved by four points at 24 hours</HEADING>
<P>Three participants in the HBOT group achieved this outcome versus five in the control group (RR 0.56, 95% CI 0.2 to 2.0, P value 0.37, for a good outcome with HBOT) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Rankin Scale score less than two at 90 days</HEADING>
<P>In <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>, five participants in the HBOT group achieved this outcome versus nine in the control group (RR 0.52, 95% CI 0.2 to 1.2, P value 0.14 for a good outcome with HBOT), while in <LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>, six participants achieved a good outcome with HBOT versus only one who received control (RR 6.0, 95% CI 0.8 to 45.2, P value 0.08). Pooled analysis was subject to high heterogeneity (I<SUP>2</SUP> = 82%) and has not been reported (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Glasgow Outcome score of five at 90 days</HEADING>
<P>Six participants in the HBOT group achieved this outcome versus 10 in the control group (RR 0.6, 95% CI 0.3 to 1.2, P value 0.13 for a good outcome with HBOT) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">NIHSS score less than two at 90 days</HEADING>
<P>Five participants in the HBOT group achieved this outcome versus eight in the control group (RR 0.59, 95% CI 0.2 to 1.4, P value 0.24 for a good outcome with HBOT) (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Deemed cured and self-caring at 21 days</HEADING>
<P>
<LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK> reported on the proportion of participants achieving 'cure' and able to provide self-care. Nine participants in the HBOT were 'cured' versus four in the control group (RR 1.9, 95% CI 0.6 to 5.6, P value 0.25 for a good outcome with HBOT) (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 5. Activities of daily living</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Barthel Index of 95 or 100 at 90 days</HEADING>
<P>Only <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> reported the number of participants with this outcome. Eight participants in the HBOT group achieved this score versus nine in the control group (RR 1.2, 95% CI 0.6 to 2.3, P value 0.6 for a good outcome with HBOT) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean Barthel Index at three weeks</HEADING>
<P>Only <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK> reported this outcome. The mean Barthel Index was higher (better) in the HBOT group (74 versus 54). The MD of 20 points was statistically significant (95% CI 13.7 to 26.3, P value &lt; 0.0001) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 6. Mean volume of infarct on CT</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mean infarct volume at four months</HEADING>
<P>Only <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> reported this outcome. The mean infarct volume was smaller in the control group (29.0 cm<SUP>3</SUP> versus 49.2 cm<SUP>3</SUP>) but not significantly so (MD 20.2 cm<SUP>3</SUP>, 95% CI -13.4 to 53.8, P value 0.24) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 7. Adverse effects of therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Ear pain</HEADING>
<P>Two trials reported on this outcome, enrolling a total of 71 participants (22% of the total) (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>). Four participants in the HBOT group suffered significant ear pain versus none in the control group (RR 4.9, 95% CI 0.6 to 39.7, P value 0.14) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
<P>Claustrophobia with related discomfiture was a significant problem in the monoplace vessels used in all trials for both arms. The severity of these problems varied across studies and was differentially reported. <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> reported 15 participants (39%) who could not complete scheduled therapy, and <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> did not report withdrawal of any participants from therapy. This is likely to reflect the single-treatment design of <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> on the one hand and the very intensive schedule planned for <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> on the other.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-10-10 12:10:31 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY_OF_RESULTS MODIFIED="2014-10-10 11:56:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>Pooled data analysis for clinical outcomes of interest could be performed with respect to only one primary analysis: death at three to six months. We found no convincing evidence that HBOT improves outcomes when applied during the acute presentation of ischaemic stroke. Pooled data from four trials did not suggest significant benefit for the case fatality rate in the six months following presentation (RR 0.97) (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>; <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK>). Although no deaths were reported in the other trials, it is not clearly stated whether all participants enrolled reached final follow-up. It is of interest that the only trial to administer the combination of a free-radical scavenger and HBOT reported three deaths in the HBOT arm and one in the control group (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>). Use of antioxidants during HBOT remains a controversial practice.</P>
<P>Some indications showed improvement on some functional and clinical scales, but this finding was not consistent. Given the heterogeneity of participants enrolled and the poor descriptors used for some of these scales, we believe that pooling of results using a standardised mean difference was not justified. In all, of the 15 comparisons made, three studies reported a total of four comparisons with a statistically significant difference in favour of HBOT, although the clinical importance of these differences is not clear (<LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> (two scores); <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK> (one score); <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK> (one score)). When estimated at longer follow-up times by <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>, these improvements were present at one year but not at six months after therapy was completed.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-10-10 11:57:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>This review has included data from 11 trials. We believe these represent all randomised trials in this area, both published and unpublished, at the time of our database search. Only seven trials with 361 participants were available for evaluation using our planned comparisons, and meta-analysis was not appropriate or possible for most outcomes. Four randomised trials enrolling a further 344 participants reported no outcomes of interest for our meta-analysis.</P>
<P>Although we have made every effort to locate further unpublished data, it remains possible that this review is subject to a positive publication bias, with generally favourable trials more likely to provide reporting. With regard to long-term outcomes following HBOT and any effect on the quality of life of these study participants, we have located no relevant data.</P>
<P>These trials were published over a 17-year period, up to 2008. We had planned to perform subgroup analyses with respect to time elapsed between stroke and institution of HBOT, dose of oxygen received and duration of treatment course. None of these analyses were appropriate given the small number of pooled analyses and the relatively uniform lack of effect shown in individual studies. In one pooled analysis that was possible, statistical heterogeneity was moderate (I<SUP>2 </SUP>= 34.7%), and the two included trials were clinically heterogenous in that one trial included only participants with embolic stroke, while using combination therapy of HBOT and a free-radical scavenger (edaravone) (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>).</P>
<P>A wide range of oxygen doses was reported across these studies: <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> gave one session only, <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK> provided an intensive regimen of eight-hourly exposures for three days, <LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK> held daily sessions for seven days, five trials reported daily therapy for 10 days (<LINK REF="STD-Li-1998" TYPE="STUDY">Li 1998</LINK>; <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK>; <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK>; <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>; <LINK REF="STD-Zhao-2008" TYPE="STUDY">Zhao 2008</LINK>) and <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK> provided therapy for 20 days. <LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>, <LINK REF="STD-Nighoghossian-1995" TYPE="STUDY">Nighoghossian 1995</LINK> and <LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK> applied modest hyperbaric pressure of 1.5 ATA versus the 2.5 ATA applied by <LINK REF="STD-Rusyniak-2003" TYPE="STUDY">Rusyniak 2003</LINK> in the single therapy session. Five trials used 2.0 ATA (<LINK REF="STD-Imai-2006" TYPE="STUDY">Imai 2006</LINK>; <LINK REF="STD-Li-1998" TYPE="STUDY">Li 1998</LINK>; <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>; <LINK REF="STD-Zhao-2008" TYPE="STUDY">Zhao 2008</LINK>). This review does not permit conclusions with regard to oxygen dosing schedule.</P>
<P>HBOT is regarded as a relatively benign intervention. Few possible major adverse effects have been described (pulmonary barotrauma, drug reactions, injury or death related to chamber fire), and none of the included studies reported any such events. Various more minor complications may occur commonly but were similarly not reported in the included studies. Visual disturbance, usually reduction in visual acuity secondary to conformational changes in the lens, is very commonly reported in perhaps as many as 50% of those given a course of 30 treatments (<LINK REF="REF-Khan-2003" TYPE="REFERENCE">Khan 2003</LINK>). Although a great majority of people experiencing visual disturbances recover spontaneously over days to weeks, a small proportion of people continue to require correction to restore sight to pretreatment levels. The second most common adverse effect associated with HBOT is barotrauma. Barotrauma can affect any air-filled cavity in the body (including middle ear, lungs and respiratory sinuses) and occurs as a direct result of compression. Aural barotrauma is by far the most common as the middle ear air space is small and is largely surrounded by bone and the sensitive tympanic membrane. Active effort by the individual is usually required to inflate the middle ear through the Eustachian tube on each side. Barotrauma is a consequence not of HBOT directly but rather of the physical conditions required to administer it. Most episodes of barotrauma are mild, easily treated or recover spontaneously and do not require the therapy to be abandoned. Less commonly, HBOT may be associated with acute neurological toxicity manifesting as seizure.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-10-10 12:02:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>A major problem for this review was the multiple outcome scales used to assess functional ability and clinical severity across trials. No scale was used and reported by more than one of these trials, making pooling of data for analysis impossible. Further, analysis of these ordinal scales to produce mean scores for group comparisons may not be appropriate. This is particularly true of Rankin, Trouillas and other unnamed recovery scales (<LINK REF="STD-Sansone-1997" TYPE="STUDY">Sansone 1997</LINK>; <LINK REF="STD-Yang-2003" TYPE="STUDY">Yang 2003</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>), given their limited range of scores from zero to 10, but none of the reports provided plots of experimental data for any of these scales to justify the use of such parametric tests. The usefulness of such scales for estimating outcomes at all has been questioned (<LINK REF="REF-Van-Gijn-1992" TYPE="REFERENCE">Van Gijn 1992</LINK>). Many of them offer distinct advantages, including the tendency to equate multiple small deficits with a few major deficits and a poor ability to estimate stroke deficit at the extremes of severity (<LINK REF="REF-Orgogozo-1998" TYPE="REFERENCE">Orgogozo 1998</LINK>). One review concluded that of nine stroke scales tested, the NIHSS was one of the three most reliable and the Barthel Index was the most reliable disability scale (<LINK REF="REF-D_x0027_Olhaberriague-1996" TYPE="REFERENCE">D'Olhaberriague 1996</LINK>).</P>
<P>The problem of multiple alternative outcome measures when potential stroke therapies are investigated is not confined to the area of HBOT. Considerable efforts are being made to develop a standard suite of outcomes to improve this situation, most notably the 'Core Outcome Measures in Effectiveness Trials (COMET) initiative.' More information is available at <A HREF="http://www.cometinitiative.org/">http://www.cometinitiative.org/</A>.</P>
<P>Other problems associated with assessing data include failure to report on primary functional outcomes, variability in time intervals between stroke event and enrolment, and variable doses of HBOT. These problems demand cautious interpretation of the results.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-10-10 12:02:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>We have made an exhaustive search of the literature, including handsearching of multiple proceedings and relevant journals in all languages. All apparently relevant study reports have been translated, and we believe we have not missed any significant studies in the area. This review has been conducted in accordance with the Cochrane methodology and is explicit. We have reported potential biases noted in contributing studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-10-10 12:10:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>A number of reviews have examined the use of HBOT in neurological conditions, including acute stroke. Despite this, the question of the efficacy and effectiveness of HBOT for this purpose remains controversial. The conclusions reached by individual authors are largely dependent on the relative weight given to animal experimentation and non-randomised clinical trials on the one hand versus randomised clinical trials on the other. <LINK REF="REF-Al_x002d_Waili-2005" TYPE="REFERENCE">Al-Waili 2005</LINK> reviewed both clinical and preclinical evidence and concluded that "previous studies have demonstrated promising results&#8212;strong enough to warrant further clinical study of HBO therapy in patients with stroke," implying agreement with our analysis that the clinical case is not yet sufficiently strong to support routine use of HBOT.</P>
<P>Similarly, in a systematic review of the clinical data, <LINK REF="REF-Carson-2005" TYPE="REFERENCE">Carson 2005</LINK> suggested that the best evidence shows no benefit of hyperbaric oxygen therapy in people with stroke. However, review authors agree that because of considerable clinical heterogeneity, particularly with respect to timing and dose of HBOT, firm conclusions are difficult to make.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-10-10 12:03:10 +0100" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2014-10-10 12:02:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>We found very few clinical data on which to base recommendations. In the 11 small trials published in full or as abstracts, evidence is insufficient to confirm that HBOT significantly affects outcomes following acute ischaemic stroke. Use of HBOT as routine therapy for people with stroke cannot be justified by this review.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-10-10 12:03:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Given the small number of participants in the included trials, we cannot be certain that benefit from HBOT can be excluded. Although a case can be made for further trials, such investigations would have to be carefully planned. More information may be useful on a subset of disease severity, particularly on the timing of therapy. The effects of differing oxygen dosage and of other therapies administered simultaneously are not known. Future trials will need to consider, in particular:<BR/>
</P>
<OL>
<LI>appropriate sample sizes with power to detect clinically important differences;</LI>
<LI>careful definition and selection of target patients;</LI>
<LI>appropriate range of oxygen doses per treatment session (pressure and time);</LI>
<LI>appropriate and carefully defined comparator therapy;</LI>
<LI>use of an effective sham therapy;</LI>
<LI>effective and explicit blinding of outcome assessors;</LI>
<LI>appropriate outcome measures, including those listed in this review;</LI>
<LI>careful elucidation of adverse effects; and</LI>
<LI>the cost-effectiveness of the treatment.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-10-10 12:03:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>The review authors acknowledge the support and suggestions of Hazel Fraser and the editors of the Cochrane Stroke Group for assistance provided in preparation of this review. In particular, we acknowledge the help of Brenda Thomas in developing the search strategy used and of Daniel Rusyniak, Peter Langhorne, Ale Algra, Anne Rowat and Steff Lewis for extensive editorial assistance provided.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-10-10 12:03:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>None known. Dr Bennett is a hyperbaric physician who does not routinely treat people with stroke.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-10-10 12:03:23 +0100" MODIFIED_BY="Hazel Fraser">
<P>MH Bennett: conception of review, background, critical appraisal, hyperbaric medicine content expert, statistical analysis, co-author for description of studies and discussion.<BR/>S Weibel: 2014 update of search, critical appraisal, clinical epidemiology expert, co-author of 2014 update<BR/>J Wasiak: search strategy and execution, critical appraisal, systematic review expert, co-author for description of studies and discussion.<BR/>C French: background to review, neurology context expert, critical appraisal.<BR/>P Kranke: critical appraisal, hyperbaric content expert, text editor.<BR/>A Schnabel: protocol development, critical appraisal, text editor.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2014-09-22 15:58:02 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1991" NAME="Anderson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson DC, Bottini AG, Jagiella WM, Westphal B, Ford S, Rockswold GL, et al</AU>
<TI>A pilot study of hyperbaric oxygen in the treatment of human stroke</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1137-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="199100"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-2008" MODIFIED="2014-09-22 15:53:21 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hong 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-09-22 15:53:21 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong L, Yu S</AU>
<TI>Efficacy of hyperbaric oxygen in treatment of ischemic stroke among young patients</TI>
<SO>Journal of Rehabilitation Medicine</SO>
<YR>2008</YR>
<VL>Suppl 46</VL>
<PG>110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imai-2006" MODIFIED="2014-09-22 15:53:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Imai 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-22 15:53:54 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imai K, Mori T, Izumoto H, Takabatake N, Kunieda T, Watanabe M</AU>
<TI>Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial</TI>
<SO>Neurologia Medico-Chirurgica</SO>
<YR>2006</YR>
<VL>46</VL>
<NO>8</NO>
<PG>373-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1998" MODIFIED="2014-04-19 05:16:17 +0100" MODIFIED_BY="Michael H Bennett" NAME="Li 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-04-19 05:16:17 +0100" MODIFIED_BY="Michael H Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li F, Chen L, Gu D</AU>
<TI>Effect of hyperbaric oxygenation on cerebral blood flow and EEG in cerebral infarction</TI>
<SO>Chinese Journal of Physical Therapy</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>2</NO>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nighoghossian-1995" NAME="Nighoghossian 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nighoghossian N, Trouillas M, Adeleine P, Salord F</AU>
<TI>Hyperbaric oxygen in the treatment of acute ischaemic stroke. A double-blind pilot study</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<PG>1369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2003" MODIFIED="2014-05-31 03:22:31 +0100" MODIFIED_BY="Michael H Bennett" NAME="Peng 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-05-31 03:22:31 +0100" MODIFIED_BY="Michael H Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng ZR, Zhu SL, Xiao PT</AU>
<TI>Changes and efficacy evaluation of serum nitrogen monoxide and oxygen-derived free radicals in patients with cerebral infarction before and after hyperbaric oxygen therapy</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>16</NO>
<PG>2318-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rusyniak-2003" NAME="Rusyniak 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rusyniak DE, Kirk MA, May JD, Kao LW, Brizendine EJ, Welch JL, et al</AU>
<TI>Hyperbaric oxygen therapy in acute ischemic stroke: results of the Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>2</NO>
<PG>571-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="12574578"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sansone-1997" MODIFIED="2009-05-27 11:29:23 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sansone 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-27 11:29:23 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sansone A, Gulotta G, Sparacia B, Alongi A, Savola G, Sparacia GV</AU>
<TI>Effect of hyperbaric oxygen therapy on neurologic recovery after focal cerebral ischaemia</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1997</YR>
<VL>78 Suppl 1</VL>
<PG>73-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-12-02 04:01:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2003" MODIFIED="2008-12-02 04:29:32 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-12-02 04:29:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Li K, He T</AU>
<TI>The effect of early hyperbaric oxygenation on the ability of daily life of patients with stroke</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>7</NO>
<PG>1221</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2004" MODIFIED="2009-05-05 16:17:05 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-05 16:17:05 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Z, Chen H, Xian M-J, Jiang X-D, Yuan Li, Mai J-H</AU>
<TI>Role of medical pressured oxygen injector in the rehabilitation of motor function and abilities of daily living at early stage of cerebral infarction</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>13</NO>
<PG>2414-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2008" MODIFIED="2014-09-22 15:58:02 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhao 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-09-22 15:58:02 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao R, Wang C, Wang Y</AU>
<TI>Changes in serum cellular adhesion molecule and matrix metalloproteinase-9 levels in patients with cerebral infarction following hyperbaric oxygen therapy. A case and intergroup control study</TI>
<SO>Neural Regeneration Research</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>11</NO>
<PG>1245-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Belokurov-1988" MODIFIED="2009-05-06 11:18:04 +0100" MODIFIED_BY="Hazel Fraser" NAME="Belokurov 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-05-06 11:18:04 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belokurov YuM, Golland AV, Kochetov KhA</AU>
<TI>Hyperbaric oxygenation in hypoxic brain injuries</TI>
<SO>Khirurgiya</SO>
<YR>1988</YR>
<VL>64</VL>
<NO>8</NO>
<PG>12-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="198800"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boschetty-1970" MODIFIED="2009-05-27 11:29:53 +0100" MODIFIED_BY="Hazel Fraser" NAME="Boschetty 1970" YEAR="1970">
<REFERENCE MODIFIED="2009-05-27 11:29:53 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boschetty V, Dostal J, Holek J</AU>
<TI>Use of hyperbaric oxygenation in acute cerebrovascular accidents. (Preliminary report)</TI>
<SO>Bratislavske Lekarske Listy</SO>
<YR>1970</YR>
<VL>53</VL>
<NO>2</NO>
<PG>160-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="5432216"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007" MODIFIED="2014-09-22 15:58:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chen 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-09-22 15:58:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen L, Li F, Gu D</AU>
<TI>Hyperbaric oxygen for cerebral blood flow and electroencephalogram in patients with acute cerebral infarction</TI>
<SO>Neural Regeneration Research</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>3</NO>
<PG>171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2012" MODIFIED="2014-09-22 15:59:00 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chen 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-09-22 15:59:00 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen C-H, Chen S-Y, Wang V, Chen C-C, Wang K-C, Chen C-H, et al</AU>
<TI>Effects of repetitive hyperbaric oxygen treatment in patients with acute cerebral infarction: a pilot study</TI>
<SO>Scientific World Journal</SO>
<YR>2012</YR>
<VL>2012</VL>
<PG>Article ID 694703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2013" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chen 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F-P, Yu X-X</AU>
<TI>Short-term effect of hyperbaric oxygen combined with edaravone and ozagrel sodium in treating progressive cerebral infarction</TI>
<SO>Chinese Journal of Evidence-Based Medicine</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>4</NO>
<PG>413-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dong-2005" MODIFIED="2014-09-22 16:00:12 +0100" MODIFIED_BY="Hazel Fraser" NAME="Dong 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-22 16:00:12 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dong X-L, Niu S-Y, Xu H-B, Han M-Y</AU>
<TI>Effects of hyperbaric oxygenation associated with panax notoginseng saponins therapy on hemorrhology indexes in patients with ischemic cerebrovascular disease</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>41</NO>
<PG>6-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Efrati-2013" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Efrati 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Efrati S, Fishlev G, Bechor Y, Volkov O, Bergan J, Kliakhandler K, et al</AU>
<TI>Hyperbaric oxygen induces late neuroplasticity in post stroke patients&#8212;randomized, prospective trial</TI>
<SO>PLoS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>1</NO>
<PG>e53716</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Efuni-1987" MODIFIED="2009-05-27 14:51:38 +0100" MODIFIED_BY="Hazel Fraser" NAME="Efuni 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-05-27 14:51:38 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Efuni SN, Lebedeva RN, Shikunova LG, Demurov EA, Mutuskina EA</AU>
<TI>Hyperbaric oxygenation in the therapy of hypoxic brain damage</TI>
<SO>Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia</SO>
<YR>1987</YR>
<VL>3</VL>
<PG>24-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="3627829"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elinsky-1984" MODIFIED="2009-05-06 11:27:20 +0100" MODIFIED_BY="Hazel Fraser" NAME="Elinsky 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-05-06 11:27:20 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elinsky MP, Rafikov AM, Ivanova NE, Kesaev SA</AU>
<TI>Therapeutic application of hyperbaric oxygenation in ischemic strokes</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1984</YR>
<VL>84</VL>
<NO>9</NO>
<PG>1321-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gusev-1990" MODIFIED="2009-05-06 11:27:34 +0100" MODIFIED_BY="Hazel Fraser" NAME="Gusev 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-05-06 11:27:34 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gusev EI, Kazantseva NV, Nifontova LA, Petukhov EB, Makarova LD, Zhuravlev AK, et al</AU>
<TI>On the mechanism of the therapeutic effect of hyperbaric oxygenation at minor differential pressure in patients with brain stroke</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1990</YR>
<VL>90</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="199000"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heyman-1966" MODIFIED="2008-10-17 07:33:53 +0100" MODIFIED_BY="[Empty name]" NAME="Heyman 1966" YEAR="1966">
<REFERENCE MODIFIED="2008-10-17 07:33:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heyman A, Saltzman HA, Whalen RE</AU>
<TI>The use of hyperbaric oxygenation in the treatment of cerebral ischemia and infarction</TI>
<SO>Circulation</SO>
<YR>1966</YR>
<VL>33</VL>
<NO>5 Suppl</NO>
<PG>II20-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="5006557"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holbach-1979" MODIFIED="2009-05-06 11:28:10 +0100" MODIFIED_BY="Hazel Fraser" NAME="Holbach 1979" YEAR="1979">
<REFERENCE MODIFIED="2009-05-06 11:28:10 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holbach KH, Wassmann H</AU>
<TI>Advantage of using hyperbaric oxygenation (HO) in combination with extra-cranial arterial bypass (EIAB) in the treatment of completed stroke</TI>
<SO>Acta Neurochirurgica</SO>
<YR>1979</YR>
<VL>28 Suppl</VL>
<PG>309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaasik-1988" MODIFIED="2009-05-06 11:28:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kaasik 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-05-06 11:28:14 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaasik A-EA, Dmitriev KK, Tomberg TA</AU>
<TI>Hyperbaric oxygenation in the treatment of patients with ischemic stroke</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1988</YR>
<VL>88</VL>
<NO>9</NO>
<PG>34-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="198800"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazantseva-2005" MODIFIED="2009-05-06 11:28:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kazantseva 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-06 11:28:47 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazantseva N, Volkova NA, Petukcov EB</AU>
<TI>Effect of normoxic curative compression on microcirculation in acute stroke</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2005</YR>
<VL>238</VL>
<PG>S407</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazantseva-2006" MODIFIED="2009-05-06 11:29:07 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kazantseva 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-06 11:29:07 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kazantseva NV</AU>
<TI>Study of the effectiveness of two curative regimens of hyperbaric therapy in acute stroke</TI>
<SO>International Journal of Stroke</SO>
<YR>2006</YR>
<VL>1 Suppl 1</VL>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lebedev-1983" MODIFIED="2009-05-27 14:52:07 +0100" MODIFIED_BY="Hazel Fraser" NAME="Lebedev 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-27 14:52:07 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lebedev VV, Isakov IuV, Pravdenkova SV</AU>
<TI>Effect of hyperbaric oxygenation on the clinical course and complications of the acute period of ischemic strokes</TI>
<SO>Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>37-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="6613431"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oshima-1990" MODIFIED="2009-05-06 11:32:01 +0100" MODIFIED_BY="Hazel Fraser" NAME="Oshima 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-05-06 11:32:01 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oshima M, Sadoshima S, Kusuda K, Yao H, Yagi H, Fujishima M</AU>
<TI>Clinical application of hyperbaric oxygen therapy for acute cerebral infarction</TI>
<SO>Undersea Biomedical Research Supplement</SO>
<YR>1990</YR>
<VL>17</VL>
<PG>140</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-1996" MODIFIED="2009-05-06 11:32:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="Pan 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-06 11:32:17 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan H</AU>
<TI>Clinical study of hyperbaric oxygen plus fonzylane on cerebral infarction</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>4</NO>
<PG>217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pravdenkova-1983" MODIFIED="2009-05-27 14:52:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Pravdenkova 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-27 14:52:35 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pravdenkova SV, Isakov IuV, Ioffe IuS</AU>
<TI>Therapeutic effect of hyperbaric oxygenation in the acute stage of an ischemic stroke</TI>
<SO>Anesteziologiia i Reanimatologiia</SO>
<YR>1983</YR>
<VL>6</VL>
<PG>26-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="6670766"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pravdenkova-1984" MODIFIED="2009-05-27 14:52:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Pravdenkova 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-05-27 14:52:54 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pravdenkova SV, Romasenko MV, Shelkovskii VN</AU>
<TI>Hyperbaric oxygenation and prevention of recurrent cerebral circulatory disorders in the acute stage of a stroke</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1984</YR>
<VL>84</VL>
<NO>8</NO>
<PG>1147-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="6495936"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarno-1972a" MODIFIED="2009-05-06 11:40:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sarno 1972a" YEAR="1972">
<REFERENCE MODIFIED="2009-05-06 11:40:54 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarno JE, Rusk HA, Diller L, Sarno MT</AU>
<TI>The effect of hyperbaric oxygen on the mental and verbal ability of stroke patients</TI>
<SO>Stroke</SO>
<YR>1972</YR>
<VL>3</VL>
<NO>1</NO>
<PG>10-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="5008300"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarno-1972b" MODIFIED="2008-11-18 05:50:04 +0000" MODIFIED_BY="[Empty name]" NAME="Sarno 1972b" YEAR="1972">
<REFERENCE MODIFIED="2008-11-18 05:50:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarno MT, Sarno JE, Diller L</AU>
<TI>The effect of hyperbaric oxygen on communication function in adults with aphasia secondary to stroke</TI>
<SO>Journal of Speech and Hearing Research</SO>
<YR>1972</YR>
<VL>15</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="5012810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soodan-1992" MODIFIED="2008-12-02 04:32:35 +0000" MODIFIED_BY="[Empty name]" NAME="Soodan 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-11-18 06:08:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soodan KS, Roy AK, Singh PK, Sing S, Hegde KP</AU>
<TI>Hyperbaric oxygen therapy in stroke cases</TI>
<SO>Indian Journal of Aerospace Medicine</SO>
<YR>1992</YR>
<VL>36</VL>
<NO>1</NO>
<PG>28-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-12-02 04:32:35 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vila-2005" MODIFIED="2014-09-22 16:05:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="Vila 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-09-22 16:05:17 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vila JF, Balcarce PE, Abiusi GR, Dominguez RO, Pisarello JB</AU>
<TI>Improvement in motor and cognitive impairment after hyperbaric oxygen therapy in a selected group of patients with cerebrovascular disease: a prospective single-blind controlled trial</TI>
<SO>Undersea and Hyperbaric Medicine</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>5</NO>
<PG>341-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xia-1995" MODIFIED="2009-05-06 11:46:44 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xia 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-05-06 11:46:44 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xia XG, Huang ZM, Zhou X</AU>
<TI>The effect of rotation magnetic field and hyperbaric oxygen on free radical metabolism in cerebral apoplexy</TI>
<SO>Chinese Journal of Physical Therapy</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>3</NO>
<PG>140-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xing-2007" MODIFIED="2009-05-06 11:47:11 +0100" MODIFIED_BY="Hazel Fraser" NAME="Xing 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-05-06 11:47:11 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xing J, Wang Y, Li Y</AU>
<TI>Clinical study on acupuncture combined with hyperbaric oxygenation for improving balance function of cerebral infarction</TI>
<SO>Chinese Acupuncture and Moxibustion</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2002" MODIFIED="2009-05-06 11:47:20 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-06 11:47:20 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang S, Li B, Liu S</AU>
<TI>The therapeutic effect of the hyperbaric oxygen on diabetic cerebral haemorrhage in the aged</TI>
<SO>Guangxi Medical Journal</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>3</NO>
<PG>303-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2000" MODIFIED="2009-05-06 11:47:41 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zhang 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-06 11:47:41 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H, Gao P, Jia Z</AU>
<TI>The evaluation of hyperbaric oxygen therapy on neuropsychological impairments in senile cerebral infarction patients</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3</NO>
<PG>209-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-05-31 03:22:31 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2014-09-22 16:05:49 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Michalski-2008" MODIFIED="2014-09-22 16:05:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="Michalski 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-09-22 16:05:49 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michalski D, Kueppers-Tiedt L, Hobohm C, Schulz A, Wagner A, Schneider D</AU>
<TI>Combination of systemic intravenous thrombolysis and hyperbaric oxygen therapy (HBOT) in acute ischemic stroke, a randomized single-blinded trial has started</TI>
<SO>International Journal of Stroke</SO>
<YR>2008</YR>
<VL>3 Suppl 1</VL>
<PG>459</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Al_x002d_Waili-2005" MODIFIED="2014-09-22 16:06:16 +0100" MODIFIED_BY="Hazel Fraser" NAME="Al-Waili 2005" TYPE="JOURNAL_ARTICLE">
<AU>Al-Waili NS, Butler GJ, Beale J, Abdullah MS, Hamilton WB, Lee BY, et al</AU>
<TI>Hyperbaric oxygen in the treatment of patients with cerebral stroke, brain trauma, and neurologic disease</TI>
<SO>Adavances in Therapy</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>6</NO>
<PG>659-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Badr-2001" NAME="Badr 2001" TYPE="JOURNAL_ARTICLE">
<AU>Badr AE, Yin W, Mychaskiw G, Zhang JH</AU>
<TI>Effect of hyperbaric oxygen on striatal metabolites: a microdialysis study in awake freely moving rats after MCA occlusion</TI>
<SO>Brain Research</SO>
<YR>2001</YR>
<VL>916</VL>
<NO>1-2</NO>
<PG>85-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="11597594"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bamford-1991" MODIFIED="2009-05-06 11:48:40 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bamford 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bamford J, Sandercock P, Dennis M, Burn J, Warlow C</AU>
<TI>Classification and natural history of clinically identifiable subtypes of cerebral infarction</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>1521-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1675378"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bath-2000" MODIFIED="2009-05-06 11:48:48 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bath 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bath PM, Lees KR</AU>
<TI>ABC of arterial and venous disease. Acute stroke</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>320</VL>
<PG>920-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10742005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2004" MODIFIED="2009-05-06 11:49:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bennett 2004" TYPE="OTHER">
<AU>Bennett MH, Connor D</AU>
<TI>The Database of Randomised Controlled Trials in Hyperbaric Medicine (DORCTIHM)</TI>
<SO>www.hboevidence.com</SO>
<YR>(accessed 14 September 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carson-2005" MODIFIED="2014-07-09 08:10:22 +0100" MODIFIED_BY="Michael H Bennett" NAME="Carson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Carson S, McDonagh M, Russman B, Helfand M</AU>
<TI>Hyperbaric oxygen therapy for stroke: a systematic review of the evidence</TI>
<SO>Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>819-833</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CASTCG-1997" MODIFIED="2009-05-06 11:50:56 +0100" MODIFIED_BY="Hazel Fraser" NAME="CASTCG 1997" TYPE="JOURNAL_ARTICLE">
<AU>Chinese Acute Stroke Trial Collaborative Group</AU>
<TI>CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1641-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9186381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clark-1982" NAME="Clark 1982" TYPE="BOOK_SECTION">
<AU>Clark JM</AU>
<TI>Oxygen toxicity</TI>
<SO>The Physiology and Medicine of Diving</SO>
<YR>1982</YR>
<PG>200-38</PG>
<EN>3rd</EN>
<ED>Bennett PB, Elliott DH</ED>
<PB>Bailliere, Tindall and Cox</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Olhaberriague-1996" NAME="D'Olhaberriague 1996" TYPE="JOURNAL_ARTICLE">
<AU>D'Olhaberriague L, Mitsias P</AU>
<TI>A reappraisal of reliability and validity studies in stroke</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>2331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-1971" NAME="Hart 1971" TYPE="JOURNAL_ARTICLE">
<AU>Hart GB, Thompson RE</AU>
<TI>The treatment of cerebral ischemia with hyperbaric oxygen (OHP)</TI>
<SO>Stroke</SO>
<YR>1971</YR>
<VL>2</VL>
<NO>3</NO>
<PG>247-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5165167"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hills-1999" NAME="Hills 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hills BA</AU>
<TI>A role for oxygen-induced osmosis in hyperbaric oxygen therapy</TI>
<SO>Medical Hypotheses</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>3</NO>
<PG>259-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10362286"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ikeda-1990" NAME="Ikeda 1990" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda Y, Long DM</AU>
<TI>The molecular basis of brain injury and brain edema: the role of oxygen free radicals</TI>
<SO>Neurosurgery</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>1-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2198480"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ingvar-1965" NAME="Ingvar 1965" TYPE="JOURNAL_ARTICLE">
<AU>Ingvar DH, Lassen NA</AU>
<TI>Treatment of focal cerebral ischaemia with hyperbaric oxygen. Report of 4 cases</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1965</YR>
<VL>41</VL>
<PG>92-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14274097"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ISTCG-1997" MODIFIED="2009-05-06 11:51:57 +0100" MODIFIED_BY="Hazel Fraser" NAME="ISTCG 1997" TYPE="JOURNAL_ARTICLE">
<AU>The International Stroke Trial Collaborative Group</AU>
<TI>The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1569-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9174558"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jain-1999" NAME="Jain 1999" TYPE="BOOK">
<AU>Jain KK</AU>
<SO>Textbook of Hyperbaric Medicine</SO>
<YR>1999</YR>
<EN>3rd</EN>
<ED>Jain KK</ED>
<PB>Hogrefe and Huber</PB>
<CY>Seattle</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="0-88937-203-9"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jain-2009" MODIFIED="2014-05-31 03:57:04 +0100" MODIFIED_BY="Michael H Bennett" NAME="Jain 2009" TYPE="BOOK">
<AU>Jain KK</AU>
<TI>Textbook of hyperbaric medicine</TI>
<SO>Textbook of Hyperbaric Medicine</SO>
<YR>2009</YR>
<EN>5th</EN>
<PB>Hogrefe and Huber</PB>
<CY>Seattle</CY>
<IDENTIFIERS>
<IDENTIFIER OTHERTYPE="ISBN" TYPE="OTHER" VALUE="978-0-88937-361-7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khan-2003" MODIFIED="2009-05-06 11:52:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Khan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Khan B, Evans AW, Easterbrook M</AU>
<TI>Refractive changes in patients undergoing hyperbaric oxygen therapy: a prospective study</TI>
<SO>Undersea and Hyperbaric Medicine</SO>
<YR>2003</YR>
<VL>24 Suppl</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kindwall-1999" NAME="Kindwall 1999" TYPE="BOOK">
<AU>Kindwall EP, Whelan HT</AU>
<SO>Hyperbaric Medicine Practice</SO>
<YR>1999</YR>
<EN>2nd</EN>
<ED>Kindwall EP, Whelan HT</ED>
<PB>Best Publishing Company</PB>
<CY>Flagstaff</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="0-941332-78-0"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mathieu-2006" MODIFIED="2014-05-31 03:57:25 +0100" MODIFIED_BY="Michael H Bennett" NAME="Mathieu 2006" TYPE="BOOK">
<AU>Mathieu 2006</AU>
<SO>Handbook on Hyperbaric Medicine</SO>
<YR>2006</YR>
<EN>1st</EN>
<PB>Springer</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mink-1995a" NAME="Mink 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Mink RB, Dutka AJ</AU>
<TI>Hyperbaric oxygen after global cerebral ischemia in rabbits does not promote brain lipid peroxidation</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1398-404</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7634811"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mink-1995b" NAME="Mink 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Mink RB, Dutka AJ</AU>
<TI>Hyperbaric oxygen after global cerebral ischemia in rabbits reduces brain vascular permeability and blood flow</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>12</NO>
<PG>2307-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7491656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" MODIFIED="2009-05-06 11:52:46 +0100" MODIFIED_BY="Hazel Fraser" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Lopez AD</AU>
<TI>Mortality by cause for eight regions of the world: Global Burden of Disease Study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1269-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9142060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neubauer-1980" NAME="Neubauer 1980" TYPE="JOURNAL_ARTICLE">
<AU>Neubauer RA, End E</AU>
<TI>Hyperbaric oxygenation as an adjunct therapy in strokes due to thrombosis. A review of 122 patients</TI>
<SO>Stroke</SO>
<YR>1980</YR>
<VL>11</VL>
<NO>3</NO>
<PG>297-300</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7394869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nighoghossian-1997" NAME="Nighoghossian 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nighoghossian N, Trouillas P</AU>
<TI>Hyperbaric oxygen in the treatment of acute ischemic stroke: an unsettled issue</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>1997</YR>
<VL>150</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9260854"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Orgogozo-1998" MODIFIED="2009-05-06 11:53:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Orgogozo 1998" TYPE="JOURNAL_ARTICLE">
<AU>Orgogozo J-M</AU>
<TI>Advantages and disadvantages of neurological scales</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1998</YR>
<VL>8 Suppl 2</VL>
<PG>2-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oriani-1996" NAME="Oriani 1996" TYPE="BOOK">
<AU>Oriani G, Marroni A, Wattel F</AU>
<SO>Handbook on Hyperbaric Medicine</SO>
<YR>1996</YR>
<EN>1st</EN>
<ED>Oriani G, Marroni A, Wattel F</ED>
<PB>Springer</PB>
<CY>Milan</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3-540-75016-9"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robertson-1989" NAME="Robertson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Robertson CS, Narayan RK, Gokaslan ZL, Pahwa R, Grossman RG, Caram P Jr, et al</AU>
<TI>Cerebral arteriovenous oxygen difference as an estimate of cerebral blood flow in comatose patients</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1989</YR>
<VL>70</VL>
<PG>222-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2913221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Selman-2004" NAME="Selman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Selman WR, Lust WD, Pundik S, Zhou Y, Ratcheson RA</AU>
<TI>Compromised metabolic recovery following spontaneous spreading depression in the penumbra</TI>
<SO>Brain Research</SO>
<YR>2004</YR>
<VL>999</VL>
<NO>2</NO>
<PG>167-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14759495"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Siesjo-1989" NAME="Siesjo 1989" TYPE="JOURNAL_ARTICLE">
<AU>Siesjo BK, Agardh CD, Bengtsson F</AU>
<TI>Free radicals and brain damage</TI>
<SO>Cerebrovascular and Brain Metabolism Review</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>165-211</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2701375"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sudlow-1997" NAME="Sudlow 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sudlow CL, Warlow CP</AU>
<TI>Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration</TI>
<SO>Stroke</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>3</NO>
<PG>491-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9056601"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sukoff-1982" NAME="Sukoff 1982" TYPE="JOURNAL_ARTICLE">
<AU>Sukoff MH, Ragatz RE</AU>
<TI>Hyperbaric oxygenation for the treatment of acute cerebral edema</TI>
<SO>Neurosurgery</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>1</NO>
<PG>29-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7057975"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SUTC-2004" MODIFIED="2014-07-10 10:56:45 +0100" MODIFIED_BY="Hazel Fraser" NAME="SUTC 2004" TYPE="COCHRANE_REVIEW">
<AU>Stroke Unit Trialists' Collaboration</AU>
<TI>Organised inpatient (stroke unit) care for stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-07-10 10:56:45 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2014-07-10 10:56:45 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000197.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thom-1993" NAME="Thom 1993" TYPE="JOURNAL_ARTICLE">
<AU>Thom SR</AU>
<TI>Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats</TI>
<SO>Toxicology and Applied Pharmacology</SO>
<YR>1993</YR>
<VL>123</VL>
<NO>2</NO>
<PG>248-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8248932"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Gijn-1992" MODIFIED="2009-05-06 11:59:15 +0100" MODIFIED_BY="Hazel Fraser" NAME="Van Gijn 1992" TYPE="JOURNAL_ARTICLE">
<AU>Van Gijn J</AU>
<TI>Measurement of outcome in stroke prevention trials</TI>
<SO>Cerebrovascular Disease</SO>
<YR>1992</YR>
<VL>2 Suppl 2</VL>
<PG>23-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2004" NAME="Wardlaw 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercock PA, Dennis MS, et al</AU>
<TI>What is the best imaging strategy for acute stroke?</TI>
<SO>Health Technology Assessment</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>1</NO>
<PG>1-180</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14731377"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yusa-1987" NAME="Yusa 1987" TYPE="JOURNAL_ARTICLE">
<AU>Yusa T, Beckman JS, Crapo JD, Freeman BA</AU>
<TI>Hyperoxia increases H2O2 production by brain in vivo</TI>
<SO>Journal of Applied Physiology</SO>
<YR>1987</YR>
<VL>63</VL>
<PG>353-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-07-10 10:57:10 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Bennett-2005" MODIFIED="2014-07-10 10:57:10 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bennett 2005" TYPE="COCHRANE_REVIEW">
<AU>Bennett MH, Wasiak J, Schnabel A, Kranke P, French C</AU>
<TI>Hyperbaric oxygen therapy for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-07-10 10:57:10 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2014-07-10 10:57:10 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD004954.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-10-10 12:11:10 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-10-10 12:11:10 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-10-10 12:03:40 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Anderson-1991">
<CHAR_METHODS MODIFIED="2009-05-05 15:54:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT stratified for disease severity<BR/>Powered to find a 30% relative improvement in HBOT group with 45 participants in each group (stopped early, no clear stopping rule applied)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-22 15:02:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>39 adults with onset of ischaemic cerebral infarction within 2 weeks and greater than 20 severity score out of 100 on a graded neurological scale designed to test for deficits in the areas supplied by the internal carotid artery<BR/>No contraindications to HBOT or unstable medical conditions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:03:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>Both groups received standard measures in neurological intensive care and vitamin E 400 mg 8-hourly during compression period<BR/>Control: sham therapy on air at 1.5 ATA for 60 minutes within 6 hours of enrolment, then every 8 hours to a total of 15 exposures (over 5 days)<BR/>HBOT: 100% oxygen at 1.5 ATA on the same schedule as above</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:03:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Graded neurological examination on a 0 to 100 scale, as at admission<BR/>Repeated at day 5, week 6, year 1<BR/>Infarct volume on CT scan at 4 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 10:30:16 +0100" MODIFIED_BY="Jenny Bellorini">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-22 15:05:01 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hong-2008">
<CHAR_METHODS MODIFIED="2014-04-19 05:19:56 +0100" MODIFIED_BY="Michael H Bennett">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-20 04:02:23 +0100" MODIFIED_BY="Michael H Bennett">
<P>86 young inpatients with ischaemic stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-19 05:20:56 +0100" MODIFIED_BY="Michael H Bennett">
<P>Routine treatment versus routine treatment plus HBOT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-19 05:22:00 +0100" MODIFIED_BY="Michael H Bennett">
<P>Nerve function deficit score, effectiveness of HBOT and routine therapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-22 15:05:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Abstract only with very little detail and no clear explanation of the results given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:04:34 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Imai-2006">
<CHAR_METHODS MODIFIED="2014-04-11 04:16:05 +0100" MODIFIED_BY="Michael H Bennett">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-10 12:04:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>Adults with acute embolic stroke (within 48 hours) in the MCA territory. Diagnosis with neurological signs, MRI findings; excluded if they received fibrinolytic treatment or had a seizure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:04:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>Both groups received standard care. Intervention group received HBOT at 2.0 ATA for 60 minutes daily for 7 days and a free-radical scavenger, edaravone 30 mg iv, before and after each HBOT session</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-22 15:06:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death, unfavourable outcomes by mRS, adverse events of otalgia and cerebral haemorrhage, median NIHSS scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 12:04:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>Methodology not well elucidated. Used combination of HBOT and free-radical scavenger</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:04:48 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Li-1998">
<CHAR_METHODS MODIFIED="2014-04-20 03:54:56 +0100" MODIFIED_BY="Michael H Bennett">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-10 12:04:41 +0100" MODIFIED_BY="Hazel Fraser">
<P>86 patients with cerebral infarction divided into 2 groups of 43 each</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:04:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>Control group received 'Salvia Miltirrhiza Co,' and HBOT group received the same therapy plus daily treatment of breathing 100% oxygen at 2.0 ATA for 120 minutes for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:04:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>Cerebral blood flow, EEG, haemorrheology and SOD</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 12:04:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>No outcomes relevant to this review reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:05:02 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Nighoghossian-1995">
<CHAR_METHODS MODIFIED="2008-12-04 04:25:07 +0000" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-10 12:04:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>34 adults (21 men) with ischaemic cerebral infarction confirmed by CT and presenting within 24 hours of onset of neurological deficit suggestive of MCA occlusion and scoring less than 80 on the Orgogozo scale (100 is normal)<BR/>No contraindications to HBOT, old infarct, congestive heart failure or uncontrolled hypertension<BR/>17 participants allocated to each arm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:05:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>Both groups received standard measures including low-dose heparin and supportive care<BR/>Control: sham therapy on air at 1.2 ATA daily for 40 minutes for 10 days<BR/>HBOT: 100% oxygen at 1.5 ATA on the same schedule as above<BR/>Participants were withdrawn from protocol if they deteriorated to coma or did not tolerate therapy (7 in total: 4 control, 3 HBOT)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:05:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Graded neurological examination on 3 scales: Orgogozo (100 to 0), Trouillas (0 to 10) and Rankin Disability Scale<BR/>Orgogozo was calculated at baseline; all were calculated at 6 months and at 1 year<BR/>Adverse effects of HBOT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 11:28:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:05:35 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Peng-2003">
<CHAR_METHODS MODIFIED="2014-09-22 15:15:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT using coin toss</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-10 12:05:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>Adults 30 years of age and older with cerebral infarction within the past 7 days, diagnosed using a 1995 conference consensus guideline. Excluded if contraindication to HBOT or already on medication that affected free-radical production</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:05:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>Both groups received standard pharmacological treatment (no details); HBOT group received 10 daily treatments at 2.3 ATA breathing 100% oxygen for 80 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:05:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>Serum nitric oxide, SOD, MDA and a clinical neurological deficit score. Clinical efficacy also estimated but meaning of this measure not clear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 12:05:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Text translated by Dr Ting Liu</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:06:00 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Rusyniak-2003">
<CHAR_METHODS MODIFIED="2008-12-04 04:26:01 +0000" MODIFIED_BY="[Empty name]">
<P>RCT stratified by time from onset to enrolment (0 to 12 hours and 12 to 24 hours) </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-05 16:00:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>33 adults with presumed ischaemic cerebral infarction with no evidence of cerebral bleed on CT and presenting within 24 hours of onset of neurological deficit<BR/>All participants scored less than 23 points on the NIHSS<BR/>No contraindications to HBOT, previous infarct within 3 months or evidence of potentially serious cardiac arrhythmia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-05 16:00:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>Control: sham therapy on oxygen at 1.14 ATA for 60 minutes<BR/>HBOT: 100% oxygen at 2.5 ATA on the same schedule as above<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:06:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>NIHSS measured at 24 hours and 90 days<BR/>Barthel Index, mRS and Glasgow Outcome Scale calculated at 90 days<BR/>Mortality<BR/>Adverse effects of HBOT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 11:28:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:06:07 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Sansone-1997">
<CHAR_METHODS MODIFIED="2009-05-05 16:01:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT reported in abstract</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-22 15:20:11 +0100" MODIFIED_BY="Hazel Fraser">
<P>17 participants (9 allocated to HBOT, 8 allocated to control) with a mean age of 61 years and presenting within 24 hours of CT-demonstrated infarction in middle or anterior cerebral arterial territory</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:06:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>Control: sham treatment of breathing air without pressurisation<BR/>HBOT: 100% oxygen at 1.5 to 1.8 ATA for 60 minutes once daily for 8 to 10 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:06:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>Neurological recovery score (10 = no disability, 0 = dead) at 6 months and at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 11:28:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:06:31 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Yang-2003">
<CHAR_METHODS MODIFIED="2009-05-05 16:07:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT of HBOT versus 'standard therapy'</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-10 12:06:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>80 participants with ischaemic stroke proven by CT or MRI within 72 hours of the event</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-22 15:21:27 +0100" MODIFIED_BY="Hazel Fraser">
<P>All participants received standard medical therapy including vasodilators, anticoagulants and 'nerve cell protectant'<BR/>HBOT: 38 participants received 100% oxygen for 80 minutes daily at 2 ATA for 10 days<BR/>Control: 32 participants received standard therapy only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:06:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>Neurological recovery was measured on a scale.</P>
<OL>
<LI>Cure: recovery to at least a self-caring state</LI>
<LI>Obvious effect: main symptoms resolved and self-caring to some extent</LI>
<LI>Effective: some evidence of recovery</LI>
<LI>No effect: no evidence of recovery</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-01 13:01:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Unusual outcome measure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:06:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Yang-2004">
<CHAR_METHODS MODIFIED="2009-05-27 11:28:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT with 3 treatment arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-10 12:06:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>120 participants with ischaemic stroke proven by CT or MRI within 72 hours of admission<BR/>Had to be first event CVA, conscious and co-operative and accompanied by neurological deficits</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:06:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>All participants received standard medical therapy and were enrolled in rehabilitation programmes as appropriate for this institution<BR/>HBOT: 60 minutes treatment at 2.0 ATA breathing 100% oxygen once daily for a total of 20 treatments<BR/>Control: standard therapy only</P>
<P>1 arm received a direct intravascular oxygen injection of 250 mL of oxygen twice daily: these participants were not included in this meta-analysis<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-22 15:22:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>Neurological deficit<BR/>Fugl-Meyer motor assessment<BR/>Barthel Index of activities of daily living</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-27 11:28:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-10-10 12:07:19 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Zhao-2008">
<CHAR_METHODS MODIFIED="2014-09-22 15:23:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT with a third control group of normal individuals</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-22 15:23:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>112 participants with acute cerebral infarction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-10 12:07:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Routine treatment group received routine drug treatment and rehabilitation exercise. HBO group received the same routine therapy plus HBO treatment at 2.0 ATA for 60 minutes plus 30 minutes of slow depressurisation to 1.0 ATA, once each day for a total of 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-10 12:07:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>Serum levels of soluble intercellular adhesion molecule, soluble vascular cell adhesion molecule, soluble E-selectin and matrix metalloproteinase-9 were detected by enzyme-linked immunosorbent assay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-22 15:23:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>No outcomes of interest were reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living<BR/>ATA: atmosphere absolute<BR/>CT: computerised tomography<BR/>CVA: cerebrovascular accident<BR/>EEG: electroencephalography<BR/>HBOT: hyperbaric oxygen therapy<BR/>ITT: intention-to-treat<BR/>iv: intravenous<BR/>MCA: middle cerebral artery<BR/>MDA: malondialdehyde<BR/>MRI: magnetic resonance imaging<BR/>mRS: modified Rankin Scale<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>RCT: randomised controlled trial<BR/>SD: standard deviation<BR/>SOD: serum superoxide dismutase</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-10-10 12:07:51 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-05-05 16:13:45 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Belokurov-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-05 16:13:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>Review only, not focused on stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 05:58:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boschetty-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 05:58:16 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparative study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-15 08:48:58 +0100" MODIFIED_BY="Michael H Bennett" STUDY_ID="STD-Chen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-15 08:48:58 +0100" MODIFIED_BY="Michael H Bennett">
<P>Both arms received HBOT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-15 08:44:04 +0100" MODIFIED_BY="Michael H Bennett" STUDY_ID="STD-Chen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-15 08:44:04 +0100" MODIFIED_BY="Michael H Bennett">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:01 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Chen-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Pseudo-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-10 12:07:44 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Dong-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-10 12:07:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not all participants had confirmed ischaemic stroke ('ischemic cerebrovascular disease')</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:16 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Efrati-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT with delayed treatment control arm but included participants 6 to 36 months after both ischaemic and haemorrhagic stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:22 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Efuni-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT, non-random controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:23 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Elinsky-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:23 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT, non-random controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:24 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Gusev-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT, case series only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-17 07:34:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heyman-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-17 07:34:22 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised and mixed aetiologies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:38 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Holbach-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>RCT, all participants received HBOT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:42 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kaasik-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:43 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kazantseva-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:46 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kazantseva-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>Abstract only, not identified as an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-31 02:11:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lebedev-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-31 02:11:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-05 16:14:34 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Oshima-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-05 16:14:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-random comparative study, no results given</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Pan-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>Abstract only, no relevant outcomes reported, probably not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-31 02:11:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pravdenkova-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-31 02:11:33 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-31 02:11:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pravdenkova-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-31 02:11:41 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:25:56 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Sarno-1972a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:25:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT, case series only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 05:50:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarno-1972b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 05:50:54 +0000" MODIFIED_BY="[Empty name]">
<P>Did not study acute stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:26:02 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Soodan-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:26:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-22 15:26:04 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Vila-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-22 15:26:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>Not an RCT and not involving acute stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-17 07:10:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xia-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-17 07:10:14 +0100" MODIFIED_BY="[Empty name]">
<P>Dose of HBOT lower than inclusion criteria (1.1 ATA)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-17 07:10:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xing-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-17 07:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>All groups received HBOT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-17 07:10:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-17 07:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>A study about haemorrhagic stroke only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-17 07:12:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-17 07:12:25 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ATA: atmosphere absolute<BR/>HBOT: hyperbaric oxygen therapy<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-05-31 03:22:31 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-10-10 12:08:01 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-10-10 12:07:57 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Michalski-2008">
<CHAR_STUDY_NAME MODIFIED="2014-10-10 12:07:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Combination of systemic intravenous thrombolysis and hyperbaric oxygen therapy (HBOT) in acute ischemic stroke; a randomised single-blinded trial has started</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-07-09 08:28:06 +0100" MODIFIED_BY="Michael H Bennett">
<P>Randomised single-blinded controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-09 08:22:05 +0100" MODIFIED_BY="Michael H Bennett">
<P>Acute stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-09 08:22:15 +0100" MODIFIED_BY="Michael H Bennett">
<P>HBOT and thrombolysis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-22 15:26:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>Infarct size, NIHSS, Barthel Index, mRS</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-09-22 15:28:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Michalski D, Kueppers-Tiedt L, Hobohm C, Schulz A, Wagner A, Schneider D<BR/>Department of Neurology, University of Leipzig, Leipzig, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-04-17 04:45:40 +0100" MODIFIED_BY="Michael H Bennett"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>HBOT: hyperbaric oxygen therapy<BR/>mRS: modified Rankin Scale<BR/>NIHSS: National Institutes of Health Stroke Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-10-10 12:11:10 +0100" MODIFIED_BY="Hazel Fraser">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-10-10 12:06:58 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:58:22 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Described as randomised, but method not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:03:54 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2008">
<DESCRIPTION>
<P>No details given; "randomly divided into two groups'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:04:35 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Imai-2006">
<DESCRIPTION>
<P>No details of methods; "patients were randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:04:50 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Li-1998">
<DESCRIPTION>
<P>'Were randomly divided'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:05:06 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Nighoghossian-1995">
<DESCRIPTION>
<P>Described as randomised, probably true</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:05:36 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Peng-2003">
<DESCRIPTION>
<P>Allocation described as by coin toss, so probably reliably random</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:59:44 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Rusyniak-2003">
<DESCRIPTION>
<P>Used sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:06:10 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Sansone-1997">
<DESCRIPTION>
<P>Study authors state that participants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:06:32 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Yang-2003">
<DESCRIPTION>
<P>Participants were described as 'divided randomly'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:06:58 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Yang-2004">
<DESCRIPTION>
<P>Study authors state that participants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 15:24:08 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Zhao-2008">
<DESCRIPTION>
<P>No details. Participants "were recruited and randomized to a HBO group (<I>n </I>= 50) and a routine treatment group (<I>n </I>= 62)." Large difference in the size of groups reduces our confidence in this process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-10-10 12:11:03 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:58:37 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Not mentioned in the text and may not have been done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-19 05:22:21 +0100" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2008">
<DESCRIPTION>
<P>No details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 15:06:25 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Imai-2006">
<DESCRIPTION>
<P>No mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-20 04:00:30 +0100" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Li-1998">
<DESCRIPTION>
<P>No mention of this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:10:44 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Nighoghossian-1995">
<DESCRIPTION>
<P>No mention in the text&#8212;probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 15:18:59 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2003">
<DESCRIPTION>
<P>No mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:59:48 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Rusyniak-2003">
<DESCRIPTION>
<P>Described in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:10:53 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Sansone-1997">
<DESCRIPTION>
<P>No mention of allocation concealment&#8212;probably did not happen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:11:03 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Yang-2003">
<DESCRIPTION>
<P>No mention of allocation concealment&#8212;probably did not happen</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:06:59 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Yang-2004">
<DESCRIPTION>
<P>No mention of allocation concealment, so probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 16:19:28 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2008">
<DESCRIPTION>
<P>No mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-10-10 12:11:10 +0100" MODIFIED_BY="Hazel Fraser" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-22 15:04:08 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Participant and outcome assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-10 12:04:10 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Hong-2008">
<DESCRIPTION>
<P>Blinding appears unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-22 15:06:27 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Imai-2006">
<DESCRIPTION>
<P>No mention of any attempt at blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-04-20 04:00:43 +0100" MODIFIED_BY="Michael H Bennett" RESULT="NO" STUDY_ID="STD-Li-1998">
<DESCRIPTION>
<P>No mention but unlikely in this trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-10 12:05:24 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Nighoghossian-1995">
<DESCRIPTION>
<P>No indication of blinding but sham therapy employed, suggesting that at least participants were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-22 15:19:00 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Peng-2003">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-10 12:06:03 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Rusyniak-2003">
<DESCRIPTION>
<P>Both participants and outcome assessors unaware of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-01 13:00:49 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Sansone-1997">
<DESCRIPTION>
<P>Sham therapy arm suggests blinding for participants and outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-10 12:06:43 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Yang-2003">
<DESCRIPTION>
<P>No evidence of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-10 12:11:10 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2004">
<DESCRIPTION>
<P>Single blinding (participant), but not clear whether this applied to HBOT/non-HBOT comparators&#8212;a sham therapy is not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-22 15:24:23 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Zhao-2008">
<DESCRIPTION>
<P>No mention, but unlikely in this study unless stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-10-10 12:07:20 +0100" MODIFIED_BY="Hazel Fraser" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-003.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-10 12:03:42 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>12 participants lost to final follow-up and all accounted for in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-19 05:22:56 +0100" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2008">
<DESCRIPTION>
<P>No information in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-22 15:06:28 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Imai-2006">
<DESCRIPTION>
<P>Complete follow-up to 90 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-10 12:04:53 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Li-1998">
<DESCRIPTION>
<P>Results for all participants reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-22 15:11:59 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Nighoghossian-1995">
<DESCRIPTION>
<P>7 participants did not reach final follow-up and were accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2003">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-10 12:06:05 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Rusyniak-2003">
<DESCRIPTION>
<P>7 participants did not reach final follow-up; 4 of these were not accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-10 12:06:20 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Sansone-1997">
<DESCRIPTION>
<P>Mean and SD were given without number of participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-22 15:21:51 +0100" MODIFIED_BY="Hazel Fraser" RESULT="NO" STUDY_ID="STD-Yang-2003">
<DESCRIPTION>
<P>10 missing participants unaccounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2004">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-10 12:07:20 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2008">
<DESCRIPTION>
<P>Numbers contributing to final outcome not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-10-10 12:06:21 +0100" MODIFIED_BY="Hazel Fraser" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>No protocol report available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2008">
<DESCRIPTION>
<P>No information in the paper and no protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Imai-2006">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Li-1998">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Nighoghossian-1995">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2003">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Rusyniak-2003">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:06:21 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Sansone-1997">
<DESCRIPTION>
<P>No protocol was available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2003">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:49:31 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Yang-2004">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 15:24:32 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2008">
<DESCRIPTION>
<P>No protocol available for checking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-10-10 12:10:38 +0100" MODIFIED_BY="Hazel Fraser" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:10:38 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1991">
<DESCRIPTION>
<P>Mortality reported as ITT, but not clear for other outcomes<BR/>Recruited some participants relatively late&#8212;up to 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-19 05:23:56 +0100" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2008">
<DESCRIPTION>
<P>Too little information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 15:06:35 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Imai-2006">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:04:55 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Li-1998">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:59:38 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Nighoghossian-1995">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-02 11:59:34 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Peng-2003">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-27 11:28:02 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Rusyniak-2003">
<DESCRIPTION>
<P>&#8212;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-10 12:06:22 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Sansone-1997">
<DESCRIPTION>
<P>This small trial may not have completed recruitment at reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 13:02:04 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2003">
<DESCRIPTION>
<P>Short report with relatively little detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-01 12:49:38 +0100" MODIFIED_BY="Hazel Fraser" RESULT="YES" STUDY_ID="STD-Yang-2004">
<DESCRIPTION>
<P>No obvious biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-22 15:24:36 +0100" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2008">
<DESCRIPTION>
<P>No clear indication of other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-10-10 12:08:28 +0100" MODIFIED_BY="Hazel Fraser">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-10-10 12:08:28 +0100" MODIFIED_BY="Hazel Fraser" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-04-20 05:05:05 +0100" MODIFIED_BY="Grade Profiler">Should hyperbaric oxygen therapy be used as an adjuvant therapy to routine therapy and rehabilitation for acute ischaemic stroke?</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Should hyperbaric oxygen therapy be used as an adjuvant therapy to routine therapy and rehabilitation for acute ischaemic stroke?</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with acute ischaemic stroke<BR/>
<B>Settings:</B> hospital inpatients<BR/>
<B>Intervention:</B> hyperbaric oxygen therapy used as adjuvant therapy to<BR/>
<B>Comparison: </B>routine therapy and rehabilitation</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Routine therapy and rehabilitation</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hyperbaric oxygen therapy used as adjuvant therapy</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Death</B>
<BR/>
<BR/>Follow-up: 3 to 6 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low-risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.34 to 2.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>144<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(7 to 55)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 1000</B>
<BR/>(27 to 220)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>120 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
<BR/>(41 to 330)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP> Small trials, with most not blinded to allocation.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-04-20 05:02:14 +0100" MODIFIED_BY="Michael H Bennett"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser">
<COMPARISON ID="CMP-001" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Mortality</NAME>
<DICH_OUTCOME CHI2="1.8645493754184166" CI_END="2.74571609520318" CI_START="0.3432013253484777" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9707385862859157" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="34.749872410840226" ID="CMP-001.01" LOG_CI_END="0.4386556295282322" LOG_CI_START="-0.46445104369507145" LOG_EFFECT_SIZE="-0.012897707083419627" METHOD="MH" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.6009901909042628" P_Q="0.21572847431184583" P_Z="0.9553558246615826" Q="1.5325640530488915" RANDOM="NO" SCALE="136.21" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="99.99999999999999" Z="0.055982404108310846">
<NAME>Death at 3 to 6 months</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.41063482839201026" CI_END="2.2039924180045554" CI_START="0.1683532275845429" DF="2" EFFECT_SIZE="0.6091381100726895" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.34321009615776593" LOG_CI_START="-0.7737785531177683" LOG_EFFECT_SIZE="-0.2152842284800012" MODIFIED="2014-04-11 05:48:15 +0100" MODIFIED_BY="Michael H Bennett" NO="1" P_CHI2="0.8143888641065502" P_Z="0.4499416584118199" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="52" WEIGHT="84.87572712850343" Z="0.7555123045054505">
<NAME>HBO alone</NAME>
<DICH_DATA CI_END="6.082230049687649" CI_START="0.14838307538965048" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7840628425461006" LOG_CI_START="-0.828615631968405" LOG_EFFECT_SIZE="-0.022276394711152253" ORDER="36661" O_E="0.0" SE="0.9472953188170158" STUDY_ID="STD-Anderson-1991" TOTAL_1="20" TOTAL_2="19" VAR="0.8973684210526316" WEIGHT="31.024149479992946"/>
<DICH_DATA CI_END="7.649243330266568" CI_START="0.01452576500886906" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8836184764944177" LOG_CI_START="-1.8378609859337425" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="36662" O_E="0.0" SE="1.5986105077709065" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="17" TOTAL_2="17" VAR="2.555555555555556" WEIGHT="22.686409307244844"/>
<DICH_DATA CI_END="4.699989050673123" CI_START="0.04711783044803384" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6720968461829978" LOG_CI_START="-1.3268147149556588" LOG_EFFECT_SIZE="-0.32735893438633035" ORDER="36663" O_E="0.0" SE="1.1741705457846552" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="17" TOTAL_2="16" VAR="1.3786764705882353" WEIGHT="31.165168341265645"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.327436276978744" CI_START="0.341848705104256" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="1.4204085702731564" LOG_CI_START="-0.46616606083383155" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-11 05:42:31 +0100" MODIFIED_BY="Michael H Bennett" NO="2" P_CHI2="1.0" P_Z="0.32150820143689296" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="15.124272871496563" Z="0.9913633524907374">
<NAME>HBO and edaravone</NAME>
<DICH_DATA CI_END="26.327436276978744" CI_START="0.341848705104256" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4204085702731564" LOG_CI_START="-0.46616606083383155" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-11 05:42:31 +0100" MODIFIED_BY="Michael H Bennett" ORDER="25" O_E="0.0" SE="1.1081832770072813" STUDY_ID="STD-Imai-2006" TOTAL_1="19" TOTAL_2="19" VAR="1.2280701754385965" WEIGHT="15.124272871496563"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<NAME>Severe functional disability</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2827065534674493" CI_START="0.10154344169622576" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3609022556390977" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.10812731359529233" LOG_CI_START="-0.9933481207782896" LOG_EFFECT_SIZE="-0.4426104035914986" METHOD="MH" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.11521933833552762" Q="0.0" RANDOM="NO" SCALE="196.11" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.575160776446058">
<NAME>No effect of therapy&#8212;participants unable to care for themselves</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.282706553467449" CI_START="0.10154344169622581" EFFECT_SIZE="0.3609022556390977" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.10812731359529226" LOG_CI_START="-0.9933481207782894" LOG_EFFECT_SIZE="-0.4426104035914986" MODIFIED="2008-12-04 05:50:03 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.647012122542377" STUDY_ID="STD-Yang-2003" TOTAL_1="38" TOTAL_2="32" VAR="0.418624686716792" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="3">
<NAME>Functional scales</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="18.069735268721885" CI_START="-7.469735268721891" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.41594808316361387" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.8134709842815707">
<NAME>Mean neurological score at day 5</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.069735268721885" CI_START="-7.469735268721891" EFFECT_SIZE="5.299999999999997" ESTIMABLE="YES" MEAN_1="43.8" MEAN_2="38.5" ORDER="36664" SD_1="2.95" SD_2="27.5" SE="6.515290775467268" STUDY_ID="STD-Anderson-1991" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="28.877489125524974" CI_START="-8.477489125524976" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.28445742412553154" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.0703597527457611">
<NAME>Mean neurological score at week 6</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.877489125524974" CI_START="-8.477489125524976" EFFECT_SIZE="10.2" ESTIMABLE="YES" MEAN_1="38.5" MEAN_2="28.3" ORDER="36665" SD_1="28.2" SD_2="25.7" SE="9.529506293406728" STUDY_ID="STD-Anderson-1991" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="26.220737584851378" CI_START="-15.020737584851382" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5945390657524483" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="0.5322699184866915">
<NAME>Mean neurological score at 1 year</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="26.220737584851378" CI_START="-15.020737584851382" EFFECT_SIZE="5.599999999999998" ESTIMABLE="YES" MEAN_1="31.4" MEAN_2="25.8" ORDER="36666" SD_1="29.1" SD_2="23.5" SE="10.520977807503161" STUDY_ID="STD-Anderson-1991" TOTAL_1="14" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.222842489364094" CI_START="-41.6228424893641" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.12777627262876953" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.5229297868022094">
<NAME>Mean Orgogozo score at 6 months</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>HBOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.222842489364094" CI_START="-41.6228424893641" EFFECT_SIZE="-18.200000000000003" ESTIMABLE="YES" MEAN_1="54.7" MEAN_2="72.9" ORDER="36667" SD_1="34.2" SD_2="27.2" SE="11.950649437500122" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.496898892609651E-32" CI_END="-4.012094412653074" CI_START="-51.78790558734693" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-27.900000000000002" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.022070648051396212" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="2.289149836460853">
<NAME>Mean Orgogozo score at 1 year</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>HBOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.012094412653077" CI_START="-51.787905587346934" EFFECT_SIZE="-27.900000000000006" ESTIMABLE="YES" MEAN_1="50.3" MEAN_2="78.2" ORDER="36668" SD_1="35.9" SD_2="26.3" SE="12.187930888410031" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="13" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1644665045490372" CI_START="-4.164466504549037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.26985780927237335" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="1.1033901052202078">
<NAME>Mean Trouillas score at 6 months</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1644665045490372" CI_START="-4.164466504549037" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="6.1" ORDER="36669" SD_1="2.5" SD_2="2.9" SE="1.3594466661459133" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="14" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.15059390708407916" CI_START="-4.249406092915921" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.03537970919800179" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.1039855306827278">
<NAME>Mean Trouillas score at 1 year</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.15059390708407916" CI_START="-4.249406092915921" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="6.3" ORDER="36670" SD_1="2.5" SD_2="2.9" SE="1.0456345673090806" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1753225036646614" CI_START="-1.3753225036646617" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.12932721454883137" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.516760296735384">
<NAME>Mean Rankin score at 6 months</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1753225036646614" CI_START="-1.3753225036646617" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="3.2" ORDER="36671" SD_1="0.8" SD_2="1.2" SE="0.3955799748262246" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1753225036646614" CI_START="-1.3753225036646617" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.12932721454883137" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.516760296735384">
<NAME>Mean Rankin score at 1 year</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1753225036646614" CI_START="-1.3753225036646617" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.0" ORDER="36672" SD_1="0.8" SD_2="1.2" SE="0.3955799748262246" STUDY_ID="STD-Nighoghossian-1995" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.576343279042645" CI_START="-2.8236567209573553" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2014-08-23 05:40:05 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="4.7139797655420015E-12" Q="0.0" RANDOM="NO" SCALE="3.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="6.913932971601799">
<NAME>Mean neurological recovery score at 12 months</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.576343279042645" CI_START="-2.8236567209573553" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="6.4" MODIFIED="2008-12-07 04:48:15 +0000" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="0.6" SD_2="0.7" SE="0.31819805153394637" STUDY_ID="STD-Sansone-1997" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.3671392428261435" CI_START="-5.632860757173857" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.025531069258496828" Q="0.0" RANDOM="NO" SCALE="6.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="2.2332711434127295">
<NAME>Neurological function deficit score at 3 weeks</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3671392428261435" CI_START="-5.632860757173857" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="20.0" MODIFIED="2008-12-07 05:00:58 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="6.0" SD_2="6.0" SE="1.343320988518935" STUDY_ID="STD-Yang-2004" TOTAL_1="38" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="4">
<NAME>Deemed to have a good outcome</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.986970739729328" CI_START="0.1604919122298975" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5647058823529412" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2981914717058606" LOG_CI_START="-0.7945468483832716" LOG_EFFECT_SIZE="-0.24817768833870552" METHOD="MH" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3733177335624863" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.890275964460719">
<NAME>NIHSS 0 or improved by 4 points at 24 hours</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HBOT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.986970739729328" CI_START="0.1604919122298975" EFFECT_SIZE="0.5647058823529412" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2981914717058606" LOG_CI_START="-0.7945468483832716" LOG_EFFECT_SIZE="-0.24817768833870552" MODIFIED="2008-12-07 04:32:24 +0000" MODIFIED_BY="[Empty name]" ORDER="36673" O_E="0.0" SE="0.6418798983622782" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="17" TOTAL_2="16" VAR="0.4120098039215686" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.446961358550739" CI_END="2.162399435469049" CI_START="0.5157399069527777" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.056047197640118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="81.64114018488158" I2_Q="78.98723482800997" ID="CMP-004.02" LOG_CI_END="0.33493591931076294" LOG_CI_START="-0.2875692624291785" LOG_EFFECT_SIZE="0.023683328440792212" METHOD="MH" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.019602477275596053" P_Q="0.029145368456464094" P_Z="0.8814475761131008" Q="4.759011923537782" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="35" WEIGHT="200.0" Z="0.14913440767912428">
<NAME>Modified Rankin score less than 2 at 90 days</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HBOT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2280646907231951" CI_START="0.22262599198710004" DF="0" EFFECT_SIZE="0.5228758169934641" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.08922124472381819" LOG_CI_START="-0.6524241323751286" LOG_EFFECT_SIZE="-0.2816014438256552" MODIFIED="2014-04-11 05:47:58 +0100" MODIFIED_BY="Michael H Bennett" NO="1" P_CHI2="1.0" P_Z="0.13664813872758536" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="1.4883897478110424">
<NAME>HBO alone</NAME>
<DICH_DATA CI_END="1.2280646907231954" CI_START="0.22262599198710004" EFFECT_SIZE="0.5228758169934641" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.08922124472381827" LOG_CI_START="-0.6524241323751286" LOG_EFFECT_SIZE="-0.2816014438256552" MODIFIED="2008-12-07 04:34:53 +0000" MODIFIED_BY="[Empty name]" ORDER="36674" O_E="0.0" SE="0.4356461657117464" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="17" TOTAL_2="16" VAR="0.1897875816993464" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="45.19567399906184" CI_START="0.796536411886396" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="1.6550968673722677" LOG_CI_START="-0.09879436660498034" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2014-04-11 05:47:15 +0100" MODIFIED_BY="Michael H Bennett" NO="2" P_CHI2="1.0" P_Z="0.08200668614002447" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.7391596419787299">
<NAME>HBO and edaravone</NAME>
<DICH_DATA CI_END="45.19567399906184" CI_START="0.796536411886396" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6550968673722677" LOG_CI_START="-0.09879436660498034" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2014-04-11 05:47:15 +0100" MODIFIED_BY="Michael H Bennett" ORDER="26" O_E="0.0" SE="1.0302443927398635" STUDY_ID="STD-Imai-2006" TOTAL_1="19" TOTAL_2="19" VAR="1.06140350877193" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1921571134990163" CI_START="0.26749220379858674" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5647058823529412" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.07633349452270334" LOG_CI_START="-0.5726888712001145" LOG_EFFECT_SIZE="-0.24817768833870552" METHOD="MH" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.13389196570965603" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.00000000000001" Z="1.4989293331010023">
<NAME>Glasgow Outcome Score of 5</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HBOT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1921571134990163" CI_START="0.26749220379858674" EFFECT_SIZE="0.5647058823529412" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.07633349452270334" LOG_CI_START="-0.5726888712001145" LOG_EFFECT_SIZE="-0.24817768833870552" MODIFIED="2008-12-07 04:37:21 +0000" MODIFIED_BY="[Empty name]" ORDER="36675" O_E="0.0" SE="0.38123895033810745" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="17" TOTAL_2="16" VAR="0.14534313725490194" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4246324861168853" CI_START="0.2428842277693822" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.15370284340630483" LOG_CI_START="-0.6146006861628526" LOG_EFFECT_SIZE="-0.2304489213782739" METHOD="MH" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.23968945523900564" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="1.175763402859294">
<NAME>NIHSS less than 2</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HBOT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4246324861168853" CI_START="0.2428842277693822" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.15370284340630483" LOG_CI_START="-0.6146006861628526" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2008-12-07 04:39:48 +0000" MODIFIED_BY="[Empty name]" ORDER="36676" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="17" TOTAL_2="16" VAR="0.2036764705882353" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.578506472918844" CI_START="0.643546389747687" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.894736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.7465179413406742" LOG_CI_START="-0.19142014171175764" LOG_EFFECT_SIZE="0.2775488998144583" METHOD="MH" MODIFIED="2008-12-07 04:42:51 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.24606466226992896" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="1.1599611049264635">
<NAME>Deemed cured and self-caring</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HBOT</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.578506472918844" CI_START="0.6435463897476871" EFFECT_SIZE="1.894736842105263" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.7465179413406742" LOG_CI_START="-0.19142014171175756" LOG_EFFECT_SIZE="0.2775488998144583" MODIFIED="2008-12-07 04:42:19 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.5509494728533887" STUDY_ID="STD-Yang-2003" TOTAL_1="38" TOTAL_2="32" VAR="0.30354532163742687" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-12-07 05:12:49 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Activities of daily living</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3220482215087648" CI_START="0.6153067621170661" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1953125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.36587123440243075" LOG_CI_START="-0.2109083120629699" LOG_EFFECT_SIZE="0.07748146116973044" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5984838731005823" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="17" WEIGHT="100.0" Z="0.5265820339602492">
<NAME>Barthel Index 95 or 100 at 90 days</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>HBOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3220482215087648" CI_START="0.6153067621170661" EFFECT_SIZE="1.1953125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.36587123440243075" LOG_CI_START="-0.2109083120629699" LOG_EFFECT_SIZE="0.07748146116973044" ORDER="36677" O_E="0.0" SE="0.3388031606985779" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="16" TOTAL_2="17" VAR="0.1147875816993464" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-13.695778155694477" CI_START="-26.304221844305523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2008-12-07 05:09:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.037207717941212E-10" Q="0.0" RANDOM="NO" SCALE="46.48" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="6.217941033627965">
<NAME>Mean Barthel Index at 3 weeks</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>HBOT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-13.695778155694477" CI_START="-26.304221844305523" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="74.0" MODIFIED="2008-12-07 05:09:13 +0000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="18.0" SD_2="10.0" SE="3.2164988204030385" STUDY_ID="STD-Yang-2004" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="6">
<NAME>Mean volume of infarct on CT</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="53.770126725881646" CI_START="-13.37012672588164" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="20.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2014-10-10 12:09:26 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.23825478381637377" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.179360233310806">
<NAME>Mean volume of infarct at 4 months</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="53.770126725881646" CI_START="-13.37012672588164" EFFECT_SIZE="20.200000000000003" ESTIMABLE="YES" MEAN_1="49.2" MEAN_2="29.0" ORDER="36678" SD_1="47.3" SD_2="41.6" SE="17.127930406210787" STUDY_ID="STD-Anderson-1991" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-04-11 05:49:16 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Adverse effects of therapy</NAME>
<DICH_OUTCOME CHI2="0.17550991664860627" CI_END="39.661009069186434" CI_START="0.6022523352500668" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.887323943661972" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.5983637594811002" LOG_CI_START="-0.22022150733750342" LOG_EFFECT_SIZE="0.6890711260717984" METHOD="MH" MODIFIED="2014-04-11 05:49:16 +0100" MODIFIED_BY="Michael H Bennett" NO="1" P_CHI2="0.6752606916604645" P_Q="1.0" P_Z="0.13746954315255433" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="35" WEIGHT="100.0" Z="1.4852804699664341">
<NAME>Ear pain</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HBOT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="126.91943808755991" CI_START="0.38607167458617" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.103528140673787" LOG_CI_START="-0.4133320606452736" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2014-04-11 05:49:16 +0100" MODIFIED_BY="Michael H Bennett" ORDER="27" O_E="0.0" SE="1.4784161409137435" STUDY_ID="STD-Imai-2006" TOTAL_1="19" TOTAL_2="19" VAR="2.185714285714286" WEIGHT="49.29577464788733"/>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="36679" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Rusyniak-2003" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="50.70422535211267"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-10-10 12:11:11 +0100" MODIFIED_BY="Hazel Fraser">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-09-22 16:10:50 +0100" MODIFIED_BY="Hazel Fraser" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAboAAAMcCAYAAAAmLWBfAABnLklEQVR42u29D2SX3////yZJkkTy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-10-10 12:11:11 +0100" MODIFIED_BY="Hazel Fraser" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUEAAAJkCAIAAAAA5QR+AAAdRUlEQVR42u3dsW4dx9nGcQIBPqRg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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-10-10 12:11:11 +0100" MODIFIED_BY="Hazel Fraser" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-09-22 16:14:37 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2014-09-22 16:13:05 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-07-21 10:21:00 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-22 16:13:05 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (Ovid)</HEADING>
<P>1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain infarction/ or hypoxia-ischemia, brain/ or carotid artery diseases/ or carotid artery thrombosis/ or carotid artery, internal, dissection/ or intracranial arterial diseases/ or cerebral arterial diseases/ or infarction, anterior cerebral artery/ or infarction, middle cerebral artery/ or infarction, posterior cerebral artery/ or exp "intracranial embolism and thrombosis"/ or exp stroke/ or vertebral artery dissection/<BR/>2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. Hyperbaric Oxygenation/<BR/>6. Oxygen Inhalation Therapy/<BR/>7. Oxygen/ae, tu<BR/>8. atmospheric pressure/<BR/>9. Atmosphere Exposure Chambers/<BR/>10. (hyperbar$ or HBO$).tw.<BR/>11. (high pressure oxygen or 100% oxygen).tw.<BR/>12. ((monoplace or multiplace) adj5 chamber$).tw.<BR/>13. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. 4 and 13<BR/>15. exp animals/ not humans.sh.<BR/>16. 14 not 15</P>
<P>The following line used to update the search: <BR/>17. limit 16 to ed=20080701-20140404</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-09-22 16:13:40 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<TITLE MODIFIED="2008-10-17 07:59:11 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-22 16:13:40 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (Ovid)</HEADING>
<P>1. stroke/ or cerebrovascular disease/ or brain infarction/ or brain stem infarction/ or cerebellum infarction/ or exp brain ischemia/ or carotid artery disease/ or exp carotid artery obstruction/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp occlusive cerebrovascular disease/ or stroke patient/ or stroke unit/<BR/>2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. oxygen therapy/ or hyperbaric oxygen/<BR/>6. *oxygen/<BR/>7. atmospheric pressure/<BR/>8. pressure chamber/<BR/>9. (hyperbar$ or HBO$).tw.<BR/>10. (high pressure oxygen or 100% oxygen).tw.<BR/>11. ((monoplace or multiplace) adj5 chamber$).tw.<BR/>12. or/5-11<BR/>13. 4 and 12<BR/>14. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not (human/ or normal human/ or human cell/)<BR/>15. 13 not 14</P>
<P>The following line used to update the search: <BR/>16. limit 15 to dd=20080701-20140404</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-09-22 16:14:17 +0100" MODIFIED_BY="Hazel Fraser" NO="3">
<TITLE MODIFIED="2009-03-24 04:08:07 +0000" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-22 16:14:17 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">CINAHL (EBSCO)</HEADING>
<P>S1 .(MH "Cerebrovascular Disorders") OR (MH "Basal Ganglia Cerebrovascular Disease") OR (MH "Carotid Artery Diseases") OR (MH "Carotid Artery Thrombosis") OR (MH "Cerebral Ischemia+") OR (MH "Intracranial Arterial Diseases") OR (MH "Cerebral Arterial Diseases") OR (MH "Intracranial Embolism and Thrombosis+") OR (MH "Stroke") or (MH "Stroke Patients")<BR/>S2 .TI ( isch#emi* N6 (stroke* or apoplex* or cerebral vasc* or cerebrovasc* or cva or attack*) ) OR AB ( isch#emi* N6 (stroke* or apoplex* or cerebral vasc* or cerebrovasc* or cva or attack*) )<BR/>S3 .TI ( (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebr* or mca* or anterior circulation or basilar artery or vertebral artery) N5 (isch?emi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*) )<BR/>S4 .AB ( (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebr* or mca* or anterior circulation or basilar artery or vertebral artery) N5 (isch?emi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*) )<BR/>S5 .S1 OR S2 OR S3 OR S4<BR/>S6 .(MH "Oxygen Therapy") OR (MH "Hyperbaric Oxygenation")<BR/>S7 .(MH "Oxygen/AE/TU") OR (MH "Oxygenation")<BR/>S8 .(MH "Atmospheric Pressure")<BR/>S9 .TI ( hyperbar* or HBO* ) OR AB ( hyperbar* or HBO* )<BR/>S10 .TI (high pressure oxygen or 100% oxygen) or AB (high pressure oxygen or 100% oxygen)<BR/>S11 .TI ( ((monoplace or multiplace) N5 chamber*) ) OR AB ( ((monoplace or multiplace) N5 chamber*) )<BR/>S12 .S6 OR S7 OR S8 OR S9 OR S10 OR S11<BR/>S13 .S5 AND S12</P>
<P>The following lines to update the search: <BR/>S14 .EM 200807-<BR/>S15 .S13 AND S14</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-09-22 16:14:37 +0100" MODIFIED_BY="Hazel Fraser" NO="4">
<TITLE MODIFIED="2014-04-08 05:44:10 +0100" MODIFIED_BY="Michael H Bennett">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-22 16:14:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>#1        [mh ^"cerebrovascular disorders"] or [mh ^"basal ganglia cerebrovascular disease"] or [mh ^"brain ischemia"] or [mh "brain infarction"] or [mh ^"hypoxia-ischemia, brain"] or [mh ^"carotid artery diseases"] or [mh ^"carotid artery thrombosis"] or [mh ^"carotid artery, internal, dissection"] or [mh ^"intracranial arterial diseases"] or [mh ^"cerebral arterial diseases"] or [mh ^"infarction, anterior cerebral artery"] or [mh ^"infarction, middle cerebral artery"] or [mh ^"infarction, posterior cerebral artery"] or [mh "intracranial embolism and thrombosis"] or [mh stroke] or [mh ^"vertebral artery dissection"]<BR/>#2        isch*mi* near/6 (stroke* or apoplex* or cerebral next vasc* or cerebrovasc* or cva or attack*):ti,ab<BR/>#3        (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle next cerebr* or mca* or "anterior circulation" or "basilar artery" or "vertebral artery") near/5 (isch*mi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*):ti,ab<BR/>#4        #1 or #2 or #3<BR/>#5        [mh ^"Hyperbaric Oxygenation"]<BR/>#6        [mh ^"Oxygen Inhalation Therapy"]<BR/>#7        [mh ^Oxygen/AE,TU]<BR/>#8        [mh ^"atmospheric pressure"]<BR/>#9        [mh ^"Atmosphere Exposure Chambers"]<BR/>#10      (hyperbar* or HBO*):ti,ab<BR/>#11      ("high pressure oxygen" or "100% oxygen"):ti,ab<BR/>#12      ((monoplace or multiplace) near/5 chamber*):ti,ab<BR/>#13      #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12<BR/>#14      #4 and #13</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in quantitative synthesis (meta-analysis): 7&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in qualitative synthesis: 11&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full-text articles assessed for eligibility: 39&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records screened: 833&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Total records after duplicates removed: 833&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified through database searching: 1454&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Additional records identified through other sources: 8&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded after review of citations and abstracts: 794&lt;/p&gt;&lt;p&gt;Ongoing studies (1)&lt;/p&gt;" WIDTH="160"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Full-text articles excluded, with reasons: 28&lt;/p&gt;&lt;p&gt;Not RCT (18), inapproporiate treatment arms (5), inapproproiate inclusion criteria (4), review article (1)&lt;/p&gt;" WIDTH="160"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>